Cross Country Healthcare (CCRN) 10-Q 3 Aug 23 2023 Q2 Quarterly report Financial data

Cover

Cover - shares	6 Months Ended
	Jun. 30, 2023	Jul. 20, 2023
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Jun. 30, 2023
Document Transition Report	false
Entity Registrant Name	CROSS COUNTRY HEALTHCARE, INC
Entity Incorporation, State or Country Code	DE
Entity File Number	0-33169
Entity Tax Identification Number	13-4066229
Entity Address, Address Line One	6551 Park of Commerce Boulevard, N.W.
Entity Address, City or Town	Boca Raton
Entity Address, State or Province	FL
Entity Address, Postal Zip Code	33487
City Area Code	561
Local Phone Number	998-2232
Title of 12(b) Security	Common stock, par value $0.0001 per share
Trading Symbol	CCRN
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		35,802,575
Entity Central Index Key	0001141103
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	Q2
Amendment Flag	false

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 673	$ 3,604
Accounts receivable, net of allowances of $18,812 in 2023 and $14,696 in 2022	484,885	641,611
Income taxes receivable	4,128	10,915
Prepaid expenses	6,753	11,067
Insurance recovery receivable	7,828	7,434
Other current assets	1,367	1,042
Total current assets	505,634	675,673
Property and equipment, net of accumulated depreciation of $20,443 in 2023 and $17,682 in 2022	24,844	19,662
Operating lease right-of-use assets	2,306	3,254
Goodwill	137,020	163,268
Other intangible assets, net	60,171	44,723
Non-current deferred tax assets	7,618	7,092
Non-current insurance recovery receivable	21,946	23,058
Other non-current assets	11,591	11,109
Total assets	771,130	947,839
Current liabilities:
Accounts payable and accrued expenses	139,555	185,507
Accrued compensation and benefits	56,021	72,605
Operating lease liabilities - current	3,292	4,132
Current portion of earnout liability	15,800	7,500
Other current liabilities	1,359	1,896
Total current liabilities	216,027	271,640
Non-current debt	31,000	148,735
Operating lease liabilities - non-current	3,150	4,880
Non-current accrued claims	32,235	35,881
Non-current earnout liability	5,200	18,000
Uncertain tax positions - non-current	9,194	7,646
Other non-current liabilities	3,976	3,838
Total liabilities	300,782	490,620
Commitments and contingencies
Stockholders' equity:
Common stock	4	4
Additional paid-in capital	255,216	292,876
Accumulated other comprehensive loss	(1,379)	(1,387)
Retained earnings	216,507	165,726
Total stockholders' equity	470,348	457,219
Total liabilities and stockholders' equity	$ 771,130	$ 947,839

CONDENSED CONSOLIDATED BALANC_2

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Statement of Financial Position [Abstract]
Accounts receivable, allowance for credit losses	$ 18,812	$ 14,696
Property and equipment, accumulated depreciation	$ 20,443	$ 17,682

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Income Statement [Abstract]
Revenue from Contract with Customer, Product and Service [Extensible List]	Service [Member]	Service [Member]	Service [Member]	Service [Member]
Revenue from services	$ 540,695	$ 753,561	$ 1,163,402	$ 1,542,293
Operating expenses:
Direct operating expenses	417,556	583,156	900,840	1,197,094
Selling, general and administrative expenses	78,938	86,009	163,198	162,862
Bad debt expense	3,134	3,192	8,042	5,561
Depreciation and amortization	4,432	3,481	9,336	6,200
Restructuring costs (benefits)	913	(1,114)	1,342	(634)
Legal settlement charges	0	0	1,125	0
Impairment charges	533	0	533	1,741
Total operating expenses	505,506	674,724	1,084,416	1,372,824
Income from operations	35,189	78,837	78,986	169,469
Other expenses (income):
Interest expense	3,149	3,857	6,839	7,378
Loss on early extinguishment of debt	1,723	1,912	1,723	1,912
Other expense (income), net	11	(1,084)	(1)	(1,092)
Income before income taxes	30,306	74,152	70,425	161,271
Income tax expense	8,961	21,258	19,644	46,394
Net income attributable to common stockholders	21,345	52,894	50,781	114,877
Other comprehensive income:
Unrealized foreign currency translation gain (loss), net of tax	1	(31)	8	(42)
Comprehensive income	$ 21,346	$ 52,863	$ 50,789	$ 114,835
Net income per share attributable to common stockholders - Basic (in dollars per share)	$ 0.60	$ 1.41	$ 1.43	$ 3.08
Net income per share attributable to common stockholders - Diluted (in dollars per share)	$ 0.60	$ 1.40	$ 1.41	$ 3.03
Weighted average common shares outstanding:
Basic (shares)	35,351	37,471	35,606	37,251
Diluted (shares)	35,524	37,757	36,041	37,866

CONDENSED CONSOLIDATED STATEM_2

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($) shares in Thousands, $ in Thousands	Total	Common Stock	Additional Paid-In Capital	Accumulated Other Comprehensive Loss, net	Retained Earnings
Beginning balance (shares) at Dec. 31, 2021		37,024
Beginning balance at Dec. 31, 2021	$ 297,528	$ 4	$ 321,552	$ (1,293)	$ (22,735)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Vesting of restricted stock (shares)		499
Vesting of restricted stock	(5,267)		(5,267)
Equity compensation	3,715		3,715
Foreign currency translation adjustment, net of taxes	(42)			(42)
Net income	114,877				114,877
Ending balance (shares) at Jun. 30, 2022		37,523
Ending balance at Jun. 30, 2022	410,811	$ 4	320,000	(1,335)	92,142
Beginning balance (shares) at Mar. 31, 2022		37,443
Beginning balance at Mar. 31, 2022	356,073	$ 4	318,125	(1,304)	39,248
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Vesting of restricted stock (shares)		80
Vesting of restricted stock	(239)		(239)
Equity compensation	2,114		2,114
Foreign currency translation adjustment, net of taxes	(31)			(31)
Net income	52,894				52,894
Ending balance (shares) at Jun. 30, 2022		37,523
Ending balance at Jun. 30, 2022	410,811	$ 4	320,000	(1,335)	92,142
Beginning balance (shares) at Dec. 31, 2022		36,303
Beginning balance at Dec. 31, 2022	457,219	$ 4	292,876	(1,387)	165,726
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Vesting of restricted stock (shares)		424
Vesting of restricted stock	(4,886)		(4,886)
Equity compensation	3,980		3,980
Stock repurchase and retirement (shares)		(1,422)
Stock repurchase and retirement	(36,483)		(36,483)
Stock repurchase excise tax	(271)		(271)
Foreign currency translation adjustment, net of taxes	8			8
Net income	50,781				50,781
Ending balance (shares) at Jun. 30, 2023		35,305
Ending balance at Jun. 30, 2023	470,348	$ 4	255,216	(1,379)	216,507
Beginning balance (shares) at Mar. 31, 2023		35,454
Beginning balance at Mar. 31, 2023	451,930	$ 4	258,144	(1,380)	195,162
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Vesting of restricted stock (shares)		49
Vesting of restricted stock	(373)		(373)
Equity compensation	2,205		2,205
Stock repurchase and retirement (shares)		(198)
Stock repurchase and retirement	(4,723)		(4,723)
Stock repurchase excise tax	(37)		(37)
Foreign currency translation adjustment, net of taxes	1			1
Net income	21,345				21,345
Ending balance (shares) at Jun. 30, 2023		35,305
Ending balance at Jun. 30, 2023	$ 470,348	$ 4	$ 255,216	$ (1,379)	$ 216,507

CONDENSED CONSOLIDATED STATEM_3

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Cash flows from operating activities
Consolidated net income	$ 50,781	$ 114,877
Adjustments to reconcile net income to net cash provided by (used in) operating activities:
Depreciation and amortization	9,336	6,200
Provision for allowances	9,807	7,213
Deferred income tax (benefit) expense	(490)	3,476
Non-cash lease expense	535	1,005
Impairment charges	533	1,741
Loss on early extinguishment of debt	1,723	1,912
Equity compensation	3,980	3,715
Other non-cash costs (benefits)	658	(301)
Changes in operating assets and liabilities:
Accounts receivable	146,443	(215,230)
Prepaid expenses and other assets	3,372	(424)
Income taxes	8,337	(9,021)
Accounts payable and accrued expenses	(66,548)	78,438
Operating lease liabilities	(2,153)	(2,674)
Other	(201)	(1,824)
Net cash provided by (used in) operating activities	166,113	(10,897)
Cash flows from investing activities
Acquisition-related settlements	182	0
Purchases of property and equipment	(7,674)	(3,848)
Net cash used in investing activities	(7,492)	(3,848)
Cash flows from financing activities
Principal payments on term loan	(73,875)	(50,438)
Debt issuance costs	0	(3,159)
Borrowings under Senior Secured Asset-Based revolving credit facility	553,419	900,112
Repayments on Senior Secured Asset-Based revolving credit facility	(599,219)	(824,312)
Cash paid for shares withheld for taxes	(4,886)	(5,267)
Principal payments on note payable	0	(2,426)
Stock repurchase and retirement	(36,483)	0
Other	(508)	(523)
Net cash (used in) provided by financing activities	(161,552)	13,987
Effect of exchange rate changes on cash	0	1
Change in cash and cash equivalents	(2,931)	(757)
Cash and cash equivalents at beginning of period	3,604	1,036
Cash and cash equivalents at end of period	$ 673	$ 279

ORGANIZATION AND BASIS OF PRESE

ORGANIZATION AND BASIS OF PRESENTATION	6 Months Ended
	Jun. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
ORGANIZATION AND BASIS OF PRESENTATION	ORGANIZATION AND BASIS OF PRESENTATION Nature of Business The accompanying condensed consolidated financial statements include the accounts of Cross Country Healthcare, Inc. and its direct and indirect wholly-owned subsidiaries (collectively, the Company). In the opinion of management, all adjustments necessary for a fair presentation of such unaudited condensed consolidated financial statements have been included. All such adjustments consisted of all normal recurring items, including the elimination of all intercompany transactions and balances. The accompanying condensed consolidated financial statements have been prepared in accordance with United States generally accepted accounting principles (U.S. GAAP) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and notes required by U.S. GAAP for complete financial statements. These operating results are not necessarily indicative of the results that may be expected for the year ending December 31, 2023. These unaudited interim condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended December 31, 2022 included in the 2022 Form 10-K. The December 31, 2022 condensed consolidated balance sheet included herein was derived from the December 31, 2022 audited consolidated balance sheet included in the 2022 Form 10-K. Certain prior year amounts have been reclassified to conform to the current year presentation. See the condensed consolidated balance sheets and the condensed consolidated statements of operations and comprehensive income.

SUMMARY OF SIGNIFICANT ACCOUNTI

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	6 Months Ended
	Jun. 30, 2023
Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Use of Estimates The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts in the condensed consolidated financial statements and accompanying notes. Management has assessed various accounting estimates and other matters, including those that require consideration of forecasted financial information, using information that is reasonably available to the Company at the time. Significant estimates and assumptions are used for, but not limited to: (i) the valuation of accounts receivable; (ii) goodwill, trade names, and other intangible assets; (iii) other long-lived assets; (iv) revenue recognition; (v) accruals for health, workers’ compensation, and professional liability claims; (vi) valuation of deferred tax assets; (vii) legal contingencies; and (viii) income taxes. Accrued insurance claims and reserves include estimated settlements from known claims and actuarial estimates for claims incurred but not reported. As additional information becomes available to the Company, its future assessment of these estimates could materially and adversely impact the Company's consolidated financial statements in future reporting periods. Actual results could differ from those estimates. Risks and Uncertainties The Company’s future results of operations and liquidity could be materially adversely affected by macroeconomic factors contributing to delays in payments from customers and inflationary pressure, uncertain or reduced demand, and the impact of any initiatives or programs that the Company may undertake to address financial and operational challenges faced by its customers. Accounts Receivable, net The timing of revenue recognition, billings, and collections results in billed and unbilled accounts receivable from customers, which are classified as accounts receivable on the condensed consolidated balance sheets and are presented net of allowances for doubtful accounts and sales allowances. Estimated revenue for the Company employees', subcontracted employees', and independent contractors’ time worked but not yet billed at June 30, 2023 and December 31, 2022 totaled $116.9 million and $152.4 million, respectively. The Company generally does not require collateral and mitigates its credit risk by performing credit evaluations and monitoring at-risk accounts. The allowance for doubtful accounts is established for losses expected to be incurred on accounts receivable balances. Accounts receivable are written off against the allowance for doubtful accounts when the Company determines amounts are no longer collectible. Judgment is required in the estimation of the allowance and the Company evaluates the collectability of its accounts receivable based on a combination of factors. The Company bases its allowance for doubtful account estimates on its historical write-off experience, current conditions, an analysis of the aging of outstanding receivable and customer payment patterns, and specific reserves for customers in adverse condition adjusted for current expectations for the customers or industry. Based on the information currently available, the Company also considered expectations of future economic condition s when estimating its allowance for doubtful accounts. The opening balance of the allowance for doubtful accounts is reconciled to the closing balance for expected credit losses as follows: 2023 2022 (amounts in thousands) Balance at January 1 $ 13,058 $ 6,087 Bad Debt Expense 4,908 2,369 Write-Offs, net of Recoveries 54 (365) Balance at March 31 18,020 8,091 Bad Debt Expense 3,134 3,192 Write-Offs, net of Recoveries (4,240) (426) Balance at June 30 $ 16,914 $ 10,857 In addition to the allowance for doubtful accounts, the Company maintains a sales allowance for billing-related adjustments which may arise in the ordinary course of business and adjustments to the reserve are recorded as contra-revenue. The sales allowance balance as of June 30, 2023 and December 31, 2022 was $1.9 million and $1.6 million, respectively. The Company’s contract terms typically require payment between 30 to 60 days from the date of invoice and are considered past due based on the particular negotiated contract terms. The majority of the Company's customers are healthcare systems with a significant percentage in acute-care facilities. No single customer accounted for more than 10% of the Company’s revenue for the three and six months ended June 30, 2023 and 2022, or the accounts receivable balance as of June 30, 2023 and December 31, 2022. Restructuring Costs The Company considers restructuring activities to be programs whereby it fundamentally changes its operations, such as closing and consolidating facilities, reducing headcount, and realigning operations in response to changing market conditions. As a result, restructuring costs on the condensed consolidated statements of operations and comprehensive income primarily include employee termination costs and lease-related exit costs. Reconciliations of the employee termination costs and lease-related exit costs beginning and ending liability balance is presented below: Employee Termination Costs Lease-Related Exit Costs (amounts in thousands) Balance at January 1, 2023 $ 799 $ 2,196 Charged (credited) to restructuring 527 (98) Payments and adjustments (539) (298) Balance at March 31, 2023 787 1,800 Charged to restructuring 913 — Payments and adjustments (608) (288) Balance at June 30, 2023 $ 1,092 $ 1,512 Recently Adopted Accounting Pronouncements On October 28, 2021, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2021-08, Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers , which requires contract assets and contract liabilities such as deferred revenue acquired in a business combination to be recognized and measured by the acquirer on the acquisition date in accordance with Accounting Standards Codification (ASC) 606, Revenue from Contracts with Customers . Generally, this amendment will result in the acquirer recognizing contract assets and contract liabilities at the same amounts recorded by the acquiree. Historically such amounts were recognized by the acquirer at fair value in acquisition accounting. This guidance is effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. The amendments should be applied prospectively to business combinations occurring on or after the effective date of the amendments. Early adoption is permitted, including adoption in an interim period. The Company adopted this standard in the first quarter of 2023 and will apply the guidance as it relates to future acquisitions.

REVENUE RECOGNITION

REVENUE RECOGNITION	6 Months Ended
	Jun. 30, 2023
Revenue from Contract with Customer [Abstract]
REVENUE RECOGNITION	REVENUE RECOGNITION The Company's revenues from customer contracts are generated from temporary staffing services and other services. Revenue is disaggregated by segment in the following table. Sales and usage-based taxes are excluded from revenue. Three Months ended June 30, 2023 Nurse Physician Total Segments (amounts in thousands) Temporary Staffing Services $ 483,560 $ 43,115 $ 526,675 Other Services 11,816 2,204 14,020 Total $ 495,376 $ 45,319 $ 540,695 Three Months ended June 30, 2022 Nurse Physician Total Segments (amounts in thousands) Temporary Staffing Services $ 712,090 $ 21,207 $ 733,297 Other Services 19,353 911 20,264 Total $ 731,443 $ 22,118 $ 753,561 Six Months ended June 30, 2023 Nurse Physician Total Segments (amounts in thousands) Temporary Staffing Services $ 1,051,210 $ 81,312 $ 1,132,522 Other Services 26,468 4,412 30,880 Total $ 1,077,678 $ 85,724 $ 1,163,402 Six Months ended June 30, 2022 Nurse Physician Total Segments (amounts in thousands) Temporary Staffing Services $ 1,461,537 $ 43,311 $ 1,504,848 Other Services 35,486 1,959 37,445 Total $ 1,497,023 $ 45,270 $ 1,542,293

ACQUISITIONS

ACQUISITIONS	6 Months Ended
	Jun. 30, 2023
Business Combination and Asset Acquisition [Abstract]
ACQUISITIONS	ACQUISITIONS HireUp On December 13, 2022, the Company purchased and acquired substantially all of the assets and assumed certain liabilities of HireUp Leadership Inc. (HireUp) for a purchase price of $6.0 million in cash, subject to adjustment, and $0.8 million in shares (or 29,811 shares) of the Company's common stock. The transaction was treated as a purchase of assets for income tax purposes. The sellers were eligible to receive up to an additional $8.0 million total in earnout cash consideration based on HireUp's revenues and Adjusted EBITDA for each of the twelve-month periods ending on the first and second anniversaries of the first day after the closing date. In the second quarter of 2023, the Company performed an analysis using multiple updated forecast scenarios and determined that the earnout would only be partially achieved. As a result, the Company recognized a decrease in the fair value of the related liabilities. The short-term portion of the liability of $3.3 million is included in the current portion of earnout liability and the long-term portion of the liability of $0.2 million is included in non-current earnout liability on the condensed consolidated balance sheets. See Note 10 - Fair Value Measurements. During the quarter ended March 31, 2023, the Company assigned the following values to other identifiable intangible assets: (i) $0.9 million to trade names with a weighted average estimated useful life of 2 years; (ii) $2.5 million to a customer list with a weighted average estimated useful life of 10 years; and (iii) $3.5 million to a database with a weighted average estimated useful life of 7 years, for a total of $6.9 million in definite life intangible assets with a weighted average estimated useful life of 7 years. The remaining excess purchase price over the fair value of net assets acquired of $3.1 million was recorded as goodwill on the Company's condensed consolidated balance sheets. The Company may record additional valuation adjustments during the remainder of the measurement period, which is not to exceed one year from the acquisition date. See Note 7 - Goodwill, Trade Names, and Other Intangible Assets. Mint On October 3, 2022, the Company purchased and acquired substantially all of the assets and assumed certain liabilities of Mint Medical Physician Staffing, LP and Lotus Medical Staffing LLC (collectively, Mint) for a purchase price of $27.0 million in cash, subject to adjustment, and $3.6 million in shares (or 114,278 shares) of the Company's common stock. The transaction was treated as a purchase of assets for income tax purposes. The sellers are eligible to receive up to an additional $10.0 million in earnout cash consideration based on Mint's revenues and gross profit for each of the twelve-month periods ending on the first and second anniversaries of the first day of the calendar month following the closing date. The short-term portion of the liability of $5.0 million is included in the current portion of earnout liability and the long-term portion of the liability of $5.0 million is included in non-current earnout liability on the condensed consolidated balance sheets. See Note 10 - Fair Value Measurements. During the quarter ended March 31, 2023, the Company assigned the following values to other identifiable intangible assets: (i) $0.4 million to trade names with a weighted average estimated useful life of 1 year; (ii) $2.3 million to a customer list with a weighted average estimated useful life of 11 years; and (iii) $12.4 million to a database with a weighted average estimated useful life of 7 years, for a total of $15.1 million in definite life intangible assets with a weighted average estimated useful life of 7 years. The remaining excess purchase price over the fair value of net assets acquired of $20.1 million was recorded as goodwill on the Company's condensed consolidated balance sheets. The Company may record additional valuation adjustments during the remainder of the measurement period, which is not to exceed one year from the acquisition date. See Note 7 - Goodwill, Trade Names, and Other Intangible Assets. Local Business On December 15, 2022, the Company purchased and acquired certain assets and assumed certain liabilities of an Ohio based business for a purchase price of $2.0 million in cash, subject to customary post-closing adjustments. The transaction was treated as a purchase of assets for income tax purposes. On December 15, 2022, an immaterial amount was recorded as goodwill on the Company's condensed consolidated balance sheets. The Company may record additional valuation adjustments during the remainder of the measurement period, which is not to exceed one year from the acquisition date. See Note 7 - Goodwill, Trade Names, and Other Intangible Assets. The above acquisitions made in 2022, HireUp, Mint, and a local business, both individually and in the aggregate, were not significant and have been accounted for using the acquisition method of accounting. The pro-forma impact on the Company's consolidated revenue from services and net income, including the pro forma effect of events that are directly attributable to the acquisitions, was not significant. Selected On December 16, 2021, the Company purchased and acquired substantially all of the assets and assumed certain liabilities of Selected, Inc. (Selected) for a purchase price of $3.5 million in cash, subject to adjustment, and $1.5 million in shares (or 59,429 shares) of the Company's common stock. The transaction was treated as a purchase of assets for income tax purposes. The sellers were eligible to receive up to an additional $1.5 million in earnout cash consideration, based on Selected's revenues for each of the twelve-month periods ending on the first and second anniversaries of the first day after the closing date. In the second quarter of 2022, the Company determined that the contingent consideration earnout related to the Selected acquisition would not be achieved for 2022 and 2023 and, as a result, the entire liability was reversed. During the quarter ended June 30, 2022, the Company assigned the following values to other identifiable intangible assets: (i) an immaterial amount to trade names with a weighted average estimated useful life of 2 years; (ii) $1.7 million to software with a weighted average estimated useful life of 5 years; and (iii) $2.9 million to a database, consisting of education professionals, with a weighted average estimated useful life of 5 years, for a total of $4.6 million in definite life intangible assets with a weighted average estimated useful life of 5 years. The remaining excess purchase price over the fair value of net assets acquired of $0.4 million was recorded as goodwill on the Company's condensed consolidated balance sheets. See Note 7 - Goodwill, Trade Names, and Other Intangible Assets. The acquisition was not significant and has been accounted for using the acquisition method of accounting. The pro-forma impact on the Company's consolidated revenue from services and net income, including the pro forma effect of events that are directly attributable to the acquisition, was not significant. Cross Country Workforce Solutions Group (CCWSG) On June 8, 2021, the Company purchased and acquired substantially all of the assets and assumed certain liabilities of Workforce Solutions Group, Inc. (WSG) for a purchase price of $25.0 million in cash and $5.0 million in shares (or 307,730 shares) of the Company's common stock. The parties agreed to a final net working capital reduction of $1.1 million, which was received in the fourth quarter of 2021. Included in the amount paid at closing and held in an escrow account was $2.0 million related to potential wage and hour indemnification claims. On December 16, 2022, this amount was released from escrow to the seller. The transaction was treated as a purchase of assets for income tax purposes. The sellers are eligible to receive an earnout based on the business' performance through three years after the acquisition date that could provide up to an additional $15.0 million in cash. In the third quarter of 2022, the Company determined that the contingent consideration earnout was achieved for the 2021 through 2022 period and, as a result, the Company made a $7.5 million earnout payment. The remaining earnout liability's carrying amount of $7.5 million is included in the current portion of earnout liability on the condensed consolidated balance sheets. See Note 10 - Fair Value Measurements. During the quarter ended September 30, 2021, the Company assigned a value to other identifiable intangible assets of $14.2 million in customer relationships with a weighted average estimated useful life of 11.5 years. The remaining excess purchase price over the fair value of net assets acquired of $22.1 million was recorded as goodwill on the Company's condensed consolidated balance sheets. See Note 7 - Goodwill, Trade Names, and Other Intangible Assets. The acquisition was not significant and has been accounted for using the acquisition method of accounting. The pro-forma impact on the Company's consolidated revenue from services and net income, including the pro forma effect of events that are directly attributable to the acquisition, was not significant. Acquisition-related costs Immaterial acquisition-related costs (benefits) associated with the Company's acquisitions have been included in selling, general and administrative expenses on its condensed consolidated statements of operations and comprehensive income.

COMPREHENSIVE INCOME

COMPREHENSIVE INCOME	6 Months Ended
	Jun. 30, 2023
Equity [Abstract]
COMPREHENSIVE INCOME	COMPREHENSIVE INCOME Total comprehensive income includes net income or loss and foreign currency translation adjustments, net of any related deferred taxes, and is included within the accompanying condensed consolidated statements of operations and comprehensive income. Certain of the Company’s foreign subsidiaries use their respective local currency as their functional currency. Assets and liabilities of these operations are translated at the exchange rates in effect on the balance sheet date. Income statement items are translated at the average exchange rates for the period. The cumulative impact of currency fluctuations related to the balance sheet translation is included in accumulated other comprehensive loss in the accompanying condensed consolidated balance sheets and was an unrealized loss of $1.4 million at June 30, 2023 and $1.5 million at December 31, 2022. The income tax impact related to components of other comprehensive income for the three and six months ended June 30, 2023 and 2022 is included in unrealized foreign currency translation gain (loss), net of tax in the condensed consolidated statements of operations and comprehensive income.

EARNINGS PER SHARE

EARNINGS PER SHARE	6 Months Ended
	Jun. 30, 2023
Earnings Per Share [Abstract]
EARNINGS PER SHARE	EARNINGS PER SHARE The following table sets forth the components of the numerator and denominator for the computation of the basic and diluted earnings per share: Three Months Ended Six Months Ended June 30, June 30, 2023 2022 2023 2022 (amounts in thousands, except per share data) Numerator: Net income attributable to common stockholders - Basic and Diluted $ 21,345 $ 52,894 $ 50,781 $ 114,877 Denominator: Weighted average common shares - Basic 35,351 37,471 35,606 37,251 Effect of diluted shares: Share-based awards 173 286 435 615 Weighted average common shares - Diluted 35,524 37,757 36,041 37,866 Net income per share attributable to common stockholders - Basic $ 0.60 $ 1.41 $ 1.43 $ 3.08 Net income per share attributable to common stockholders - Diluted $ 0.60 $ 1.40 $ 1.41 $ 3.03 The following table represents the share-based awards that could potentially dilute net income per share attributable to common stockholders in the future that were not included in the computation of diluted net income per share attributable to common stockholders because to do so would have been anti-dilutive for the periods presented. Three Months Ended Six Months Ended June 30, June 30, 2023 2022 2023 2022 (amounts in thousands) Share-based awards — 220 — 110

GOODWILL, TRADE NAMES, AND OTHE

GOODWILL, TRADE NAMES, AND OTHER INTANGIBLE ASSETS	6 Months Ended
	Jun. 30, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
GOODWILL, TRADE NAMES, AND OTHER INTANGIBLE ASSETS	GOODWILL, TRADE NAMES, AND OTHER INTANGIBLE ASSETS The Company had the following acquired intangible assets: June 30, 2023 December 31, 2022 Gross Accumulated Net Gross Accumulated Net (amounts in thousands) Intangible assets subject to amortization: Databases $ 49,330 $ 25,447 $ 23,883 $ 33,430 $ 22,033 $ 11,397 Customer relationships 52,538 24,011 28,527 47,738 21,672 26,066 Non-compete agreements 4 4 — 4 3 1 Trade names 1,330 644 686 30 16 14 Software 1,700 525 1,175 1,700 355 1,345 Other intangible assets, net $ 104,902 $ 50,631 $ 54,271 $ 82,902 $ 44,079 $ 38,823 Intangible assets not subject to amortization: Trade names, indefinite-lived $ 5,900 $ 5,900 As of June 30, 2023, estimated annual amortization expense was as follows: (amounts in thousands) Years Ending December 31: 2023 $ 5,702 2024 10,481 2025 9,571 2026 8,362 2027 6,191 Thereafter 13,964 $ 54,271 The changes in the carrying amount of goodwill by reportable segment are as follows: Nurse Physician Total (amounts in thousands) Balances as of December 31, 2022 Aggregate goodwill acquired $ 395,119 $ 78,621 $ 473,740 Accumulated impairment loss (269,874) (40,598) (310,472) Goodwill, net of impairment loss 125,245 38,023 163,268 Changes to aggregate goodwill in 2023 Goodwill acquisition adjustments (a) (11,148) (15,100) (26,248) Balances as of June 30, 2023 Aggregate goodwill acquired 383,971 63,521 447,492 Accumulated impairment loss (269,874) (40,598) (310,472) Goodwill, net of impairment loss $ 114,097 $ 22,923 $ 137,020 ________________ (a) Represents adjustments to the fair value of the identifiable net assets acquired, with a corresponding offset to goodwill, made during the measurement period related to the acquisitions of HireUp, Mint, and a local business. The Company may record additional adjustments related to these acquisitions during the remainder of the measurement period, which is not to exceed one year from the acquisition date. Upon conclusion of the measurement period, any subsequent adjustments will be recorded to earnings. See Note 4 - Acquisitions. Goodwill, Trade Names, and Other Intangible Assets Impairment The Company tests reporting units’ goodwill and intangible assets with indefinite lives for impairment annually during the fourth quarter and more frequently if impairment indicators exist. The Company performs quarterly qualitative assessments of significant events and circumstances such as reporting units’ historical and current results, assumptions regarding future performance, strategic initiatives and overall economic factors, and macro-economic developments, to determine the existence of potential indicators of impairment and assess if it is more likely than not that the fair value of reporting units or intangible assets is less than their carrying value. If indicators of impairments are identified a quantitative impairment test is performed. As of June 30, 2023, the Company performed a qualitative assessment of each of its reporting units and determined it was not more likely than not that the fair value of its reporting units dropped below their carrying value. A lthough management believes that the Company's current estimates and assumptions utilized in its qualitative testing are reasonable and supportable, there can be no assurance that the estimates and assumptions management used for purposes of its assessment as of June 30, 2023 will prove to be accurate predictions of future performance.

DEBT

DEBT	6 Months Ended
	Jun. 30, 2023
Debt Disclosure [Abstract]
DEBT	DEBT The Company's long-term debt consists of the following: June 30, 2023 December 31, 2022 Principal Debt Issuance Costs Principal Debt Issuance Costs (amounts in thousands) Term Loan, interest of 10.14% at December 31, 2022 $ — $ — $ 73,875 $ (1,940) Senior Secured Asset-Based Loan, interest of 6.66% and 5.90% at June 30, 2023 and December 31, 2022, respectively 31,000 (3,034) 76,800 (3,437) Long-term debt $ 31,000 $ (3,034) $ 150,675 $ (5,377) As of June 30, 2023 and December 31, 2022, all debt is included in long-term debt on the condensed consolidated balance sheets. The Company has elected to present the debt issuance costs associated with its revolving line-of-credit as an asset, which is included in other non-current assets on the condensed consolidated balance sheets. As a result, the long-term debt in the above table will not agree to long-term debt on the condensed consolidated balance sheets herein. In addition to its scheduled payments, the Company made optional prepayments of $50.0 million on its term loan on June 23, 2022 and October 26, 2022, totaling $100.0 million, to reduce interest costs. The Company was entitled to determine the application of the prepayments, which were applied to all future amortization payments, with the balance applied to the remaining balloon payment in 2027. On June 30, 2023, the Company repaid all outstanding obligations under the term loan, and terminated the Term Loan Agreement (as defined below). As of June 30, 2023, the aggregate schedule for maturities of debt was as follows: Term Loan Senior Secured Asset-Based Loan (amounts in thousands) Through Years Ending December 31: 2023 $ — $ — 2024 — — 2025 — — 2026 — — 2027 — 31,000 Thereafter — — Total $ — $ 31,000 2021 Term Loan Credit Agreement On June 8, 2021, the Company entered into a Term Loan Credit Agreement (Term Loan Agreement) with certain lenders identified therein (collectively, the Lenders) and Wilmington Trust , National Association as administrative agent and collateral agent, pursuant to which the Lenders extended to the Company a six-year second lien subordinated term loan in the amount of $100.0 million (term loan). The term loan had an interest rate of one-month London Inter-Bank Offered Rate (LIBOR) plus 5.75% per annum, subject to a 0.75% LIBOR floor. The borrowings under the Term Loan Agreement generally bore interest at a variable rate based on either LIBOR or Base Rate (as defined in the Term Loan Agreement) and were subject to mandatory prepayments of principal payable in quarterly installments. The term loan was secured by a second-priority security interest in the collateral as defined in the Loan Agreement (as defined below). The lien priority, relative rights, and other creditors’ rights issues in respect of the collateral lenders are set forth in the Intercreditor Agreement, dated June 8, 2021 (Intercreditor Agreement). On November 18, 2021, the Company amended its Term Loan Agreement (Term Loan First Amendment), which provided the Company an incremental term loan in an aggregate amount equal to $75.0 million. Additionally, the Term Loan First Amendment increased the aggregate amount of all increases (as defined in the Term Loan Agreement) to be no greater than $115.0 million. In conjunction with the Term Loan First Amendment, the Company entered into the Term Loan First Amendment to the Intercreditor Agreement effective as of November 18, 2021. On April 14, 2023, the Company amended its Term Loan Agreement (Term Loan Second Amendment), which provided the option for all or a portion of the borrowings to bear interest at a rate based on the Secured Overnight Financing Rate (SOFR) or the Base Rate, at the election of the borrowers, plus an applicable margin. With respect to any SOFR loan, the rate per annum was equal to the Term SOFR (as defined in the Term Loan Second Amendment) for the interest period plus an adjustment of 10 basis points due to the credit spread associated with the transition to SOFR. In the second and fourth quarters of 2022, the Company made early prepayments totaling $100 million, and incurred prepayment premiums of $1.0 million pursuant to the Term Loan Agreement. Debt issuance costs of $1.4 million and $1.3 million were written off in the second and fourth quarters of 2022, respectively. On June 30, 2023, the Company repaid all outstanding obligations of $73.9 million under the term loan, and terminated the Term Loan Agreement. As a result, debt issuance costs of $1.7 million were written off in the second quarter of 2023. There were no prepayment premiums associated with the payoff and all subsidiary guarantees of the term loan were automatically released. Any prepayment premiums and write-off of debt issuance costs are included as loss on early extinguishment of debt in the condensed consolidated statements of operations and comprehensive income. 2019 Asset-Based Loan Agreement Effective October 25, 2019, the Company terminated its prior senior credit facility and entered into an asset-based loan agreement, by and among the Company and certain of its domestic subsidiaries, as borrowers or guarantors, Wells Fargo, PNC Bank N.A., as well as other Lenders (as defined therein) from time to time parties thereto (Loan Agreement). The Loan Agreement provides for a five-year revolving senior secured asset-based credit facility (ABL) in the aggregate principal amount of up to $120.0 million, including a sublimit for swing loans up to $15.0 million and a $35.0 million sublimit for standby letters of credit. On June 30, 2020, the Company amended its Loan Agreement (First Amendment), which increased the current aggregate committed size of the ABL from $120.0 million to $130.0 million. All other terms, conditions, covenants, and pricing of the Loan Agreement remained the same. On March 8, 2021, the Company amended its Loan Agreement (Second Amendment), which increased the current aggregate committed size of the ABL from $130.0 million to $150.0 million, increased certain borrowing base sub-limits, and decreased both the cash dominion event and financial reporting triggers. On June 8, 2021, the Company amended its Loan Agreement (Third Amendment), which permits the incurrence of indebtedness and grant of security as set forth in the Loan Agreement and in accordance with the Intercreditor Agreement, and provides mechanics relating to a transition away from LIBOR as a benchmark interest rate to a replacement alternative benchmark rate or mechanism for loans made in U.S. dollars. On November 18, 2021, the Company amended its Loan Agreement (Fourth Amendment), whereby the permitted indebtedness (as defined in the Loan Agreement), was increased to $175.0 million. On March 21, 2022, the Company amended its Loan Agreement (Fifth Amendment), which increased the current aggregate committed size of the ABL from $150.0 million to $300.0 million, extended the credit facility for an additional five years, and increased certain borrowing base sub-limits. In addition, the agreement provides the option for all or a portion of the borrowings to bear interest at a rate based on the SOFR or the Base Rate, at the election of the borrowers, plus an applicable margin. The applicable margin will increase 10 basis points due to the credit spread associated with the transition to SOFR. These amendments were treated as modifications of debt and, as a result, the associated fees and costs were included in debt issuance costs and will be amortized ratably over the remaining term of the Loan Agreement. Availability of the ABL commitments is subject to a borrowing base of up to 85% of secured eligible accounts receivable, subject to adjustment at certain quality levels, minus customary reserves and subject to customary adjustments. Revolving loans and letters of credit issued under the Loan Agreement reduce availability under the ABL on a dollar-for-dollar basis. At June 30, 2023, borrowing base availability under the ABL was $289.2 million and the Company had $31.0 million of borrowings drawn, as well as $18.2 million of letters of credit outstanding related to workers' compensation and professional liability policies, leaving $240.0 million of excess availability. As of June 30, 2023, the interest rate spreads and fees under the Loan Agreement were based on SOFR plus 1.60% for the revolving portion of the borrowing base. The Base Rate (as defined by the Loan Agreement) margin would have been 0.50% for the revolving portion . The SOFR and Base Rate margins are subject to monthly pricing adjustments, pursuant to a pricing matrix based on the Company’s excess availability under the revolving credit facility. In addition, the facility is subject to an unused line fee, letter of credit fees, and an administrative fee. The unused line fee is 0.375% of the average daily unused portion of the revolving credit facility. The Loan Agreement contains various restrictions and covenants applicable to the Company and its subsidiaries, including a covenant to maintain a minimum fixed charge coverage ratio. The Company was in compliance with this covenant as of June 30, 2023. Obligations under the ABL are secured by substantially all the assets of the borrowers and guarantors, subject to customary exceptions.

LEASES

LEASES	6 Months Ended
	Jun. 30, 2023
Leases [Abstract]
LEASES	LEASES The Company's lease population of its right-of-use assets and lease liabilities is substantially related to the rental of office space. The Company enters into lease agreements as a lessee that may include options to extend or terminate early. Some of these real estate leases require variable payments of property taxes, insurance, and common area maintenance, in addition to base rent. Certain of the leases have provisions for free rent months during the lease term and/or escalating rent payments and, particularly for the Company’s longer-term leases for its corporate offices, it has received incentives to enter into the leases, such as receiving up to a specified dollar amount to construct tenant improvements. These leases do not include residual value guarantees, covenants, or other restrictions. Beginning in the second quarter of 2020, in connection with the global pandemic, the Company expedited restructuring plans and either reduced or fully vacated leased office space. The decision and change in the use of space resulted in a right-of-use asset impairment charge of $1.5 million for the three months ended March 31, 2022. This loss was determined by comparing the fair value of the impacted right-of-use assets to the carrying value of the assets as of the impairment measurement date. The fair value of the right-of-use assets was based on the estimated sublease income for the space taking into consideration the time period it will take to obtain a subtenant, the applicable discount rate, and the sublease rate. For the three months ended March 31, 2022, the Company wrote off an immaterial amount of leasehold improvements and other property and equipment related to these locations. The Company did not record any lease-related impairment charges for the three and six months ended June 30, 2023 or the three months ended June 30, 2022. The measurement of the right-of-use asset impairments, using the assumptions described, is a Level 3 fair value measurement. See Note 10 - Fair Value Measurements for a description of Level 3 inputs. The table below presents the lease-related assets and liabilities included on the condensed consolidated balance sheets: Classification on Condensed Consolidated Balance Sheets: June 30, 2023 December 31, 2022 (amounts in thousands) Operating lease right-of-use assets $ 2,306 $ 3,254 Operating lease liabilities - current $ 3,292 $ 4,132 Operating lease liabilities - non-current $ 3,150 $ 4,880 June 30, 2023 December 31, 2022 Weighted average remaining lease term 2 years 2.3 years Weighted average discount rate 6.35 % 6.31 % The table below reconciles the undiscounted cash flows for each of, and total of, the remaining years to the operating lease liabilities (which do not include short-term leases) recorded on the condensed consolidated balance sheets as of June 30, 2023: (amounts in thousands) Years Ending December 31: 2023 $ 1,989 2024 2,860 2025 1,913 2026 69 2027 47 Total minimum lease payments 6,878 Less: amount of lease payments representing interest (436) Present value of future minimum lease payments 6,442 Less: operating lease liabilities - current (3,292) Operating lease liabilities - non-current $ 3,150 Other Information The table below provides information regarding supplemental cash flows: Six Months Ended June 30, 2023 2022 (amounts in thousands) Supplemental Cash Flow Information: Cash paid for amounts included in the measurement of operating lease liabilities $ 2,434 $ 3,135 Right-of-use assets acquired under operating lease $ 88 $ 60 The components of lease expense are as follows: Three Months Ended June 30, 2023 2022 (amounts in thousands) Amounts Included in Condensed Consolidated Statements of Operations and Comprehensive Income: Operating lease expense $ 412 $ 645 Short-term lease expense $ 738 $ 1,241 Variable and other lease costs $ 275 $ (1,110) Six Months Ended June 30, 2023 2022 (amounts in thousands) Amounts Included in Condensed Consolidated Statements of Operations and Comprehensive Income: Operating lease expense $ 904 $ 1,447 Short-term lease expense $ 1,818 $ 2,385 Variable and other lease costs $ 273 $ (353) Operating lease expense, short-term lease expense, and variable and other lease costs are included in selling, general and administrative expenses, direct operating expenses, and restructuring costs (benefits) in the condensed consolidated statements of operations and comprehensive income, depending on the nature of the leased asset. Operating lease expense is reported net of sublease income, which is not material. Variable and other lease costs for the three and six months ended June 30, 2022 included a benefit associated with the early termination of one of the Company's leases for corporate offices which was previously restructured. As of June 30, 2023, the Company did not have any material operating leases that had not yet commenced. The Company does not have any finance lease contracts related to other equipment rentals which are not included in the above disclosures.

FAIR VALUE MEASUREMENTS

FAIR VALUE MEASUREMENTS	6 Months Ended
	Jun. 30, 2023
Fair Value Disclosures [Abstract]
FAIR VALUE MEASUREMENTS	FAIR VALUE MEASUREMENTS Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. A fair value hierarchy was established which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. There are three levels of inputs that may be used to measure fair value: Level 1 —Quoted prices in active markets for identical assets or liabilities. Level 2 —Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 3 —Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. Items Measured at Fair Value on a Recurring Basis: The Company’s financial assets/liabilities required to be measured on a recurring basis were primarily its: (i) deferred compensation asset included in other non-current assets; and (ii) deferred compensation liability included in other non-current liabilities on its condensed consolidated balance sheets. Deferred compensation —The Company utilizes Level 1 inputs to value its deferred compensation assets and liabilities. The Company’s deferred compensation assets and liabilities are measured using publicly available indices, as per the plan documents. The estimated fair value of the Company’s financial assets and liabilities measured on a recurring basis is as follows: Fair Value Measurements June 30, 2023 December 31, 2022 (amounts in thousands) Financial Assets: (Level 1) Deferred compensation asset $ 3,103 $ 2,477 Financial Liabilities: (Level 1) Deferred compensation liability $ 2,932 $ 2,507 Items Measured at Fair Value on a Non-Recurring Basis: The Company's non-financial assets, such as goodwill, trade names, other intangible assets, right-of-use assets, and property and equipment, are measured at fair value when there is an indicator of impairment and are recorded at fair value only when an impairment charge is recognized. The three months ended June 30, 2023 included the write-off of an abandoned IT project, resulting in a $0.5 million impairment charge. The six months ended June 30, 2022 included impairment charges to right-of-use assets along with related property and equipment in connection with leases that were vacated. Accordingly, as of June 30, 2022, these assets were recorded at fair value using Level 3 inputs. See Note 9 - Leases for more information about these fair value measurements. Other Fair Value Disclosures: Financial instruments not measured or recorded at fair value in the condensed consolidated balance sheets consist of cash and cash equivalents, accounts receivable, and accounts payable and accrued expenses. The estimated fair value of accounts receivable and accounts payable and accrued expenses approximate their carrying amount due to the short-term nature of these instruments. Other financial instruments not measured or recorded at fair value include: (i) ABL, (ii) term loan, and (iii) through (v) earnout liabilities related to the WSG, Mint, and HireUp acquisitions, as discussed below. (i) The carrying amount of the Company's ABL approximates fair value because the interest rates are variable and reflective of market rates. (ii) On June 30, 2023, the Company repaid all outstanding obligations of $73.9 million under the term loan, and terminated the Term Loan Agreement. See Note 8 - Debt. Prior to termination, the estimated fair value of the Company's term loan was calculated applying an interest rate lattice model using Level 2 inputs from available market information. (iii) Potential earnout payments related to the WSG acquisition are contingent upon meeting certain performance requirements based on 2021 through 2023 performance. The Company performed an analysis using multiple forecast scenarios to determine the fair value of the earnout liability. In the third quarter of 2022, the Company determined that the contingent consideration earnout related to the WSG acquisition was achieved for the 2021 through 2022 period and, as a result, the Company made a $7.5 million earnout payment. The remaining $7.5 million earnout liability's carrying amount approximates fair value and is included in the current portion of earnout liability on the condensed consolidated balance sheets. See Note 4 - Acquisitions. (iv) Potential earnout payments related to the Mint acquisition are contingent upon meeting certain performance requirements based on 2022 through 2024 performance. The Company performed an analysis using multiple forecast scenarios to determine the fair value of the earnout liability. The earnout liability's carrying amount approximates fair value and the short-term portion of the liability of $5.0 million is included in the current portion of earnout liability and the long-term portion of the liability of $5.0 million is included in non-current earnout liability on the condensed consolidated balance sheets. See Note 4 - Acquisitions. (v) Potential earnout payments related to the HireUp acquisition are contingent upon meeting certain performance requirements based on 2022 through 2024 performance. In the second quarter of 2023, the Company performed an analysis using multiple updated forecast scenarios and determined that the earnout would only be partially achieved. As a result, the Company recognized a decrease in the fair value of the related liabilities. The short-term portion of the liability of $3.3 million is included in the current portion of earnout liability and the long-term portion of the liability of $0.2 million is included in non-current earnout liability on the condensed consolidated balance sheets. See Note 4 - Acquisitions. The carrying amounts and estimated fair value of the Company’s significant financial instruments that were not measured at fair value are as follows: June 30, 2023 December 31, 2022 Carrying Fair Carrying Fair (amounts in thousands) Financial Liabilities: (Level 2) Senior Secured Asset-Based Loan $ 31,000 $ 31,000 $ 76,800 $ 76,800 Term Loan, net $ — $ — $ 73,875 $ 71,221 Earnout Liability (WSG) $ 7,500 $ 7,500 $ 7,500 $ 7,500 Earnout Liability (Mint) $ 10,000 $ 10,000 $ 10,000 $ 10,000 Earnout Liability (HireUp) $ 3,500 $ 3,500 $ 8,000 $ 8,000 Concentration of Credit Risk: See discussion of credit losses and allowance for doubtful accounts in Note 2 - Summary of Significant Accounting Policies. Overall, based on the large number of customers in differing geographic areas, primarily throughout the United States and its territories, the Company believes the concentration of credit risk is limited.

STOCKHOLDERS' EQUITY

STOCKHOLDERS' EQUITY	6 Months Ended
	Jun. 30, 2023
Equity [Abstract]
STOCKHOLDERS' EQUITY	STOCKHOLDERS’ EQUITY Stock Repurchase Program On August 16, 2022, the Company's Board of Directors authorized a new stock repurchase program (the New Repurchase Program), whereby the Company may repurchase up to $100.0 million of its shares of common stock, subject to the terms of its current credit agreements. The shares may be repurchased from time-to-time in the open market or in privately negotiated transactions. The New Repurchase Program was effective immediately and may be discontinued at any time at the Board of Directors' discretion. In addition to the repurchase of $100.0 million of its shares of common stock under the New Repurchase Program, the Company was authorized to continue to repurchase any remaining shares available for repurchase under the Company's previous stock repurchase program, which was approved by the Board of Directors on February 28, 2008 (the Prior Repurchase Program). Upon completion of the authorized number of shares available for repurchase under the Prior Repurchase Program, the Company commenced repurchases under the New Repurchase Program during the third quarter of 2022. During the fourth quarter of 2022, the Company entered into a Rule 10b5-1 Repurchase Plan to allow for share repurchases during the Company's blackout periods. On May 1, 2023, the Company’s Board of Directors authorized approximately $59.0 million in additional share repurchases, such that, effective for trades made after May 3, 2023, the aggregate amount available for stock repurchases under the New Repurchase Program was $100.0 million. The shares can be repurchased from time-to-time in the open market or in privately negotiated transactions. Decisions regarding the amount and the timing of repurchases under the New Repurchase Program will be subject to the Company’s available liquidity and cash on hand, applicable legal requirements, the terms of the Company’s Loan Agreement and Term Loan Agreement, general market conditions, and other factors. The New Repurchase Program does not obligate the Company to repurchase any particular number of shares of common stock and may be discontinued by the Board of Directors at any time. During the three months ended June 30, 2023, the Company repurchased and retired a total of 198,463 shares of common stock for $4.7 million, at an average price of $23.78 per share. During the six months ended June 30, 2023, the Company repurchased and retired a total of 1,421,867 shares of common stock for $36.5 million, at an average price of $25.64 per share. During the three and six months ended June 30, 2022, the Company did not repurchase any shares of its common stock. As of June 30, 2023, the Company had $98.4 million remaining for share repurchase under the New Repurchase Program, subject to certain conditions in the Company's Loan Agreement. At June 30, 2023, the Company had 35,305,025 unrestricted shares of common stock outstanding. Share-Based Payments On May 19, 2020, the Company's stockholders approved the Cross Country Healthcare, Inc. 2020 Omnibus Incentive Plan (2020 Plan), which replaced the Cross Country Healthcare, Inc. 2017 Omnibus Incentive Plan (2017 Plan), and applies to awards granted after May 19, 2020. The remaining shares available for grant under the 2017 Plan were cancelled and no further awards will be granted under that plan. The 2020 Plan generally mirrors the terms of the 2017 Plan and includes the following provisions: (i) an aggregate share reserve of 3,000,000 shares; (2) annual dollar and share limits of awards granted to employees and consultants, as well as non-employee directors, based on type of award; (3) awards granted generally will be subject to a minimum one-year vesting schedule; and (4) awards may be granted under the 2020 Plan until March 24, 2030. The following table summarizes restricted stock awards and performance stock awards activity issued under the 2017 Plan and the 2020 Plan (Plans) for the six months ended June 30, 2023: Restricted Stock Awards Performance Stock Awards Number of Weighted Number of Target Weighted Unvested restricted stock awards, January 1, 2023 674,508 $ 14.53 476,086 $ 12.56 Granted 314,503 $ 22.80 200,487 $ 19.23 Vested (402,419) $ 12.40 (238,253) $ 6.74 Forfeited (21,405) $ 20.93 (4,785) $ 16.83 Unvested restricted stock awards, June 30, 2023 565,187 $ 20.40 433,535 $ 18.80 Restricted stock awards granted under the Company’s Plans entitle the holder to receive, at the end of a vesting period, a specified number of shares of the Company’s common stock. Share-based compensation expense is measured by the market value of the Company’s stock on the date of grant. Awards granted to non-employee directors under the 2020 Plan will vest on the first anniversary of such grant date, or earlier subject to retirement eligibility . In addition, effective for the three months ended June 30, 2020, the Company implemented modified guidelines that provide for accelerated vesting of restricted stock grants on the last date of service when a retirement-eligible director retires. Pursuant to the Plans, the number of target shares that are issued for performance-based stock awards are determined based on the level of attainment of the targets. During the first quarter of 2023, the Company's Compensation Committee of the Board of Directors approved a 120% level of attainment for the 2020 performance-based share awards, resulting in the issuance of 238,253 performance shares that vested on March 31, 2023. During the three and six months ended June 30, 2023, $2.2 million and $4.0 million, respectively, was included in selling, general and administrative expenses related to share-based payments, and a net of 49,582 and 424,274 shares, respectively, of common stock were issued upon the vesting of restricted and performance stock. During the three and six months ended June 30, 2022, $2.1 million and $3.7 million, respectively, was included in selling, general and administrative expenses related to share-based payments, and a net of 80,200 and 499,700 shares, respectively, of common stock were issued upon the vesting of restricted and performance stock.

SEGMENT DATA

SEGMENT DATA	6 Months Ended
	Jun. 30, 2023
Segment Reporting [Abstract]
SEGMENT DATA	SEGMENT DATA The Company’s segments offer services to its customers as described below: ● Nurse and Allied Staffing – Nurse and Allied Staffing provides traditional staffing, recruiting, and value-added total talent solutions including: temporary and permanent placement of travel and local nurse and allied professionals, and healthcare leaders within nursing, allied, physician, human resources, and finance, MSP services, education healthcare services, in-home care services, and outsourcing services. In addition, Nurse and Allied Staffing provides retained search services for healthcare professionals, as well as contingent search and recruitment process outsourcing services. Its customers include: public and private acute-care and non-acute care hospitals, government facilities, local and national healthcare plans, managed care providers, public schools and charter schools, outpatient clinics, ambulatory care facilities, physician practice groups, and many other healthcare providers throughout the United States. ● Physician Staffing – Physician Staffing provides physicians in many specialties, as well as certified registered nurse anesthetists, nurse practitioners, and physician assistants as independent contractors on temporary assignments throughout the United States at various healthcare facilities, such as acute and non-acute care facilities, medical group practices, government facilities, and managed care organizations. The Company evaluates performance of each segment primarily based on revenue and contribution income. The Company defines contribution income as income (loss) from operations before depreciation and amortization, acquisition and integration-related (benefits) costs, restructuring (benefits) costs, legal settlement charges, impairment charges, and corporate overhead. The Company does not evaluate, manage, or measure performance of segments using asset information; accordingly, total asset information by segment is not prepared or disclosed. The information in the following table is derived from the segments’ internal financial information as used for corporate management purposes. Certain corporate expenses are not allocated to and/or among the operating segments. Information on operating segments and a reconciliation to income from operations for the periods indicated are as follows: Three Months Ended Six Months Ended June 30, June 30, 2023 2022 2023 2022 (amounts in thousands) Revenue from services: Nurse and Allied Staffing $ 495,376 $ 731,443 $ 1,077,678 $ 1,497,023 Physician Staffing 45,319 22,118 85,724 45,270 $ 540,695 $ 753,561 $ 1,163,402 $ 1,542,293 Contribution income: Nurse and Allied Staffing $ 56,481 $ 97,567 $ 123,650 $ 207,668 Physician Staffing 3,541 1,220 5,265 2,985 60,022 98,787 128,915 210,653 Corporate overhead (a) 18,891 17,583 37,547 33,837 Depreciation and amortization 4,432 3,481 9,336 6,200 Restructuring costs (benefits) 913 (1,114) 1,342 (634) Legal settlement charges — — 1,125 — Impairment charges 533 — 533 1,741 Other costs (b) 64 — 46 40 Income from operations $ 35,189 $ 78,837 $ 78,986 $ 169,469 _______________ (a) Corporate overhead includes unallocated executive leadership and other centralized corporate functional support costs such as finance, IT, legal, human resources, and marketing, as well as public company expenses and corporate-wide projects (initiatives). (b) Other costs include acquisition and integration-related (benefits) costs.

CONTINGENCIES

CONTINGENCIES	6 Months Ended
	Jun. 30, 2023
Commitments and Contingencies Disclosure [Abstract]
CONTINGENCIES	CONTINGENCIES Legal Proceedings From time to time, the Company is involved in various litigation, claims, investigations, and other proceedings that arise in the ordinary course of its business. These proceedings primarily relate to employee-related matters that include individual and collective claims, professional liability, tax, and payroll practices. The Company establishes reserves when available information indicates that a loss is probable and an amount or range of loss can be reasonably estimated. These assessments are performed at least quarterly and are based on the information available to management at the time and involve significant management judgment to determine the probability and estimated amount of potential losses, if any. Based on the available information considered in its reviews, the Company adjusts its loss contingency accruals and its disclosures as may be required. Actual outcomes or losses may differ materially from those estimated by the Company's current assessments, including available insurance recoveries, which would impact the Company's profitability. Adverse developments in existing litigation claims or legal proceedings involving the Company or new claims could require management to establish or increase litigation reserves or enter into unfavorable settlements or satisfy judgments for monetary damages for amounts in excess of current reserves, which could adversely affect the Company's financial results. The Company believes the outcome of any outstanding loss contingencies as of June 30, 2023 will not have a material adverse effect on its business, financial condition, results of operations, or cash flows. Sales and Other State Non-Income Tax Liabilities The Company's sales and other state non-income tax filings are subject to routine audits by authorities in the jurisdictions where it conducts business in the United States which may result in assessments of additional taxes. The Company accrues sales and other non-income tax liabilities based on the Company's best estimate of its probable liability utilizing currently available information and interpretation of relevant tax regulations. Given the nature of the Company's business, significant subjectivity

INCOME TAXES

INCOME TAXES	6 Months Ended
	Jun. 30, 2023
Income Tax Disclosure [Abstract]
INCOME TAXES	INCOME TAXES For the three and six months ended June 30, 2023 and 2022, the Company calculated the provision for income taxes by applying an annual effective tax rate to ordinary income for the interim reporting period. The Company’s effective tax rate was 29.6% and 27.9%, including the impact of discrete items, and 30.0%, excluding discrete items, for the three and six months ended June 30, 2023, respectively. The Company’s effective tax rate was 28.7% and 28.8%, including the impact of discrete items, and 28.9% and 29.5%, excluding discrete items, for the three and six months ended June 30, 2022, respectively. The effective tax rates for the three and six months ended June 30, 2023 and 2022 were primarily impacted by federal and state taxes. The tax years 2012 through 2022 remain open to examination by certain taxing jurisdictions to which the Company is subject to tax.

RELATED PARTY TRANSACTIONS

RELATED PARTY TRANSACTIONS	6 Months Ended
	Jun. 30, 2023
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS	RELATED PARTY TRANSACTIONS The Company has entered into an arrangement for digital marketing services provided by a firm that is related to Mr. Kevin C. Clark, the Company's non-executive Chairman of the Board of Directors since April 1, 2022, and the Company's Co-Founder & Chief Executive Officer through March 31, 2022. Mr. Clark is a minority shareholder in the firm's parent company and is a member of the parent company's Board of Directors. Management believes the terms of the arrangement are equivalent to those prevailing in an arm's-length transaction and have been approved by the Company through its related party process. The digital marketing firm manages a limited number of digital publishers covering various Company brands for a monthly management fee. During the three and six months ended June 30, 2023 and 2022, the Company incurred an immaterial amount in expenses. The Company had immaterial payable balances at June 30, 2023 and December 31, 2022. The Company provides services to entities which are affiliated with certain members of the Company’s Board of Directors. Management believes the services were conducted on terms equivalent to those prevailing in an arm's-length transaction. Revenue related to these transactions was $0.4 million and $0.6 million for the three and six months ended June 30, 2023, respectively, and $0.5 million and $0.9 million for the three and six months ended June 30, 2022, respectively. Accounts receivable due from these entities was an immaterial amount at June 30, 2023 and December 31, 2022. Following the WSG acquisition on June 8, 2021, the Company continued to rent WSG's headquarters. The Chief Executive Officer and Founder of WSG, who is currently a business unit president with the Company, is an agent of the lessor. The lease for WSG's headquarters was terminated at the end of the first quarter of 2023. Accordingly, the Company paid no rent expense for these premises for the three months ended June 30, 2023 and had no payable balance at June 30, 2023.

Pay vs Performance Disclosure

Pay vs Performance Disclosure - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Pay vs Performance Disclosure
Net Income (Loss)	$ 21,345	$ 52,894	$ 50,781	$ 114,877

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended
	Jun. 30, 2023
Trading Arrangements, by Individual
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

SUMMARY OF SIGNIFICANT ACCOUN_2

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	6 Months Ended
	Jun. 30, 2023
Accounting Policies [Abstract]
Nature of Business	Nature of Business The accompanying condensed consolidated financial statements include the accounts of Cross Country Healthcare, Inc. and its direct and indirect wholly-owned subsidiaries (collectively, the Company). In the opinion of management, all adjustments necessary for a fair presentation of such unaudited condensed consolidated financial statements have been included. All such adjustments consisted of all normal recurring items, including the elimination of all intercompany transactions and balances.
Basis of Accounting	The accompanying condensed consolidated financial statements have been prepared in accordance with United States generally accepted accounting principles (U.S. GAAP) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and notes required by U.S. GAAP for complete financial statements. These operating results are not necessarily indicative of the results that may be expected for the year ending December 31, 2023. These unaudited interim condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended December 31, 2022 included in the 2022 Form 10-K. The December 31, 2022 condensed consolidated balance sheet included herein was derived from the December 31, 2022 audited consolidated balance sheet included in the 2022 Form 10-K. Certain prior year amounts have been reclassified to conform to the current year presentation. See the condensed consolidated balance sheets and the condensed consolidated statements of operations and comprehensive income.
Use of Estimates	Use of Estimates The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts in the condensed consolidated financial statements and accompanying notes. Management has assessed various accounting estimates and other matters, including those that require consideration of forecasted financial information, using information that is reasonably available to the Company at the time. Significant estimates and assumptions are used for, but not limited to: (i) the valuation of accounts receivable; (ii) goodwill, trade names, and other intangible assets; (iii) other long-lived assets; (iv) revenue recognition; (v) accruals for health, workers’ compensation, and professional liability claims; (vi) valuation of deferred tax assets; (vii) legal contingencies; and (viii) income taxes. Accrued insurance claims and reserves include estimated settlements from known claims and actuarial estimates for claims incurred but not reported. As additional information becomes available to the Company, its future assessment of these estimates
Risks and Uncertainties	Risks and Uncertainties The Company’s future results of operations and liquidity could be materially adversely affected by macroeconomic factors contributing to delays in payments from customers and inflationary pressure, uncertain or reduced demand, and the impact of any initiatives or programs that the Company may undertake to address financial and operational challenges faced by its customers.
Accounts Receivable, net	Accounts Receivable, net The timing of revenue recognition, billings, and collections results in billed and unbilled accounts receivable from customers, which are classified as accounts receivable on the condensed consolidated balance sheets and are presented net of allowances for doubtful accounts and sales allowances. Estimated revenue for the Company employees', subcontracted employees', and independent contractors’ time worked but not yet billed at June 30, 2023 and December 31, 2022 totaled $116.9 million and $152.4 million, respectively. The Company generally does not require collateral and mitigates its credit risk by performing credit evaluations and monitoring at-risk accounts. The allowance for doubtful accounts is established for losses expected to be incurred on accounts receivable balances. Accounts receivable are written off against the allowance for doubtful accounts when the Company determines amounts are no longer collectible. Judgment is required in the estimation of the allowance and the Company evaluates the collectability of its accounts receivable based on a combination of factors. The Company bases its allowance for doubtful account estimates on its historical write-off experience, current conditions, an analysis of the aging of outstanding receivable and customer payment patterns, and specific reserves for customers in adverse condition adjusted for current expectations for the customers or industry. Based on the information currently available, the Company also considered expectations of future economic condition s when estimating its allowance for doubtful accounts.
Restructuring Costs	Restructuring Costs The Company considers restructuring activities to be programs whereby it fundamentally changes its operations, such as closing and consolidating facilities, reducing headcount, and realigning operations in response to changing market conditions. As a result, restructuring costs on the condensed consolidated statements of operations and comprehensive income primarily include employee termination costs and lease-related exit costs.
Recently Adopted Accounting Pronouncements	Recently Adopted Accounting Pronouncements On October 28, 2021, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2021-08, Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers , which requires contract assets and contract liabilities such as deferred revenue acquired in a business combination to be recognized and measured by the acquirer on the acquisition date in accordance with Accounting Standards Codification (ASC) 606, Revenue from Contracts with Customers . Generally, this amendment will result in the acquirer recognizing contract assets and contract liabilities at the same amounts recorded by the acquiree. Historically such amounts were recognized by the acquirer at fair value in acquisition accounting. This guidance is effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. The amendments should be applied prospectively to business combinations occurring on or after the effective date of the amendments. Early adoption is permitted, including adoption in an interim period. The Company adopted this standard in the first quarter of 2023 and will apply the guidance as it relates to future acquisitions.

SUMMARY OF SIGNIFICANT ACCOUN_3

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	6 Months Ended
	Jun. 30, 2023
Accounting Policies [Abstract]
Schedule of Allowance for Doubtful Accounts	The opening balance of the allowance for doubtful accounts is reconciled to the closing balance for expected credit losses as follows: 2023 2022 (amounts in thousands) Balance at January 1 $ 13,058 $ 6,087 Bad Debt Expense 4,908 2,369 Write-Offs, net of Recoveries 54 (365) Balance at March 31 18,020 8,091 Bad Debt Expense 3,134 3,192 Write-Offs, net of Recoveries (4,240) (426) Balance at June 30 $ 16,914 $ 10,857
Schedule of Restructuring and Related Costs	Reconciliations of the employee termination costs and lease-related exit costs beginning and ending liability balance is presented below: Employee Termination Costs Lease-Related Exit Costs (amounts in thousands) Balance at January 1, 2023 $ 799 $ 2,196 Charged (credited) to restructuring 527 (98) Payments and adjustments (539) (298) Balance at March 31, 2023 787 1,800 Charged to restructuring 913 — Payments and adjustments (608) (288) Balance at June 30, 2023 $ 1,092 $ 1,512

REVENUE RECOGNITION (Tables)

REVENUE RECOGNITION (Tables)	6 Months Ended
	Jun. 30, 2023
Revenue from Contract with Customer [Abstract]
Schedule of Disaggregation of Revenue	The Company's revenues from customer contracts are generated from temporary staffing services and other services. Revenue is disaggregated by segment in the following table. Sales and usage-based taxes are excluded from revenue. Three Months ended June 30, 2023 Nurse Physician Total Segments (amounts in thousands) Temporary Staffing Services $ 483,560 $ 43,115 $ 526,675 Other Services 11,816 2,204 14,020 Total $ 495,376 $ 45,319 $ 540,695 Three Months ended June 30, 2022 Nurse Physician Total Segments (amounts in thousands) Temporary Staffing Services $ 712,090 $ 21,207 $ 733,297 Other Services 19,353 911 20,264 Total $ 731,443 $ 22,118 $ 753,561 Six Months ended June 30, 2023 Nurse Physician Total Segments (amounts in thousands) Temporary Staffing Services $ 1,051,210 $ 81,312 $ 1,132,522 Other Services 26,468 4,412 30,880 Total $ 1,077,678 $ 85,724 $ 1,163,402 Six Months ended June 30, 2022 Nurse Physician Total Segments (amounts in thousands) Temporary Staffing Services $ 1,461,537 $ 43,311 $ 1,504,848 Other Services 35,486 1,959 37,445 Total $ 1,497,023 $ 45,270 $ 1,542,293

EARNINGS PER SHARE (Tables)

EARNINGS PER SHARE (Tables)	6 Months Ended
	Jun. 30, 2023
Earnings Per Share [Abstract]
Schedule of Components of Numerator and Denominator for Computation of Basic and Diluted Earnings per Share	The following table sets forth the components of the numerator and denominator for the computation of the basic and diluted earnings per share: Three Months Ended Six Months Ended June 30, June 30, 2023 2022 2023 2022 (amounts in thousands, except per share data) Numerator: Net income attributable to common stockholders - Basic and Diluted $ 21,345 $ 52,894 $ 50,781 $ 114,877 Denominator: Weighted average common shares - Basic 35,351 37,471 35,606 37,251 Effect of diluted shares: Share-based awards 173 286 435 615 Weighted average common shares - Diluted 35,524 37,757 36,041 37,866 Net income per share attributable to common stockholders - Basic $ 0.60 $ 1.41 $ 1.43 $ 3.08 Net income per share attributable to common stockholders - Diluted $ 0.60 $ 1.40 $ 1.41 $ 3.03
Schedule of Antidilutive Securities	The following table represents the share-based awards that could potentially dilute net income per share attributable to common stockholders in the future that were not included in the computation of diluted net income per share attributable to common stockholders because to do so would have been anti-dilutive for the periods presented. Three Months Ended Six Months Ended June 30, June 30, 2023 2022 2023 2022 (amounts in thousands) Share-based awards — 220 — 110

GOODWILL, TRADE NAMES, AND OT_2

GOODWILL, TRADE NAMES, AND OTHER INTANGIBLE ASSETS (Tables)	6 Months Ended
	Jun. 30, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Acquired Intangible Assets	The Company had the following acquired intangible assets: June 30, 2023 December 31, 2022 Gross Accumulated Net Gross Accumulated Net (amounts in thousands) Intangible assets subject to amortization: Databases $ 49,330 $ 25,447 $ 23,883 $ 33,430 $ 22,033 $ 11,397 Customer relationships 52,538 24,011 28,527 47,738 21,672 26,066 Non-compete agreements 4 4 — 4 3 1 Trade names 1,330 644 686 30 16 14 Software 1,700 525 1,175 1,700 355 1,345 Other intangible assets, net $ 104,902 $ 50,631 $ 54,271 $ 82,902 $ 44,079 $ 38,823 Intangible assets not subject to amortization: Trade names, indefinite-lived $ 5,900 $ 5,900
Schedule of Estimated Annual Amortization Expense	As of June 30, 2023, estimated annual amortization expense was as follows: (amounts in thousands) Years Ending December 31: 2023 $ 5,702 2024 10,481 2025 9,571 2026 8,362 2027 6,191 Thereafter 13,964 $ 54,271
Schedule of Changes in Carrying Amount of Goodwill by Segment	The changes in the carrying amount of goodwill by reportable segment are as follows: Nurse Physician Total (amounts in thousands) Balances as of December 31, 2022 Aggregate goodwill acquired $ 395,119 $ 78,621 $ 473,740 Accumulated impairment loss (269,874) (40,598) (310,472) Goodwill, net of impairment loss 125,245 38,023 163,268 Changes to aggregate goodwill in 2023 Goodwill acquisition adjustments (a) (11,148) (15,100) (26,248) Balances as of June 30, 2023 Aggregate goodwill acquired 383,971 63,521 447,492 Accumulated impairment loss (269,874) (40,598) (310,472) Goodwill, net of impairment loss $ 114,097 $ 22,923 $ 137,020 ________________ (a) Represents adjustments to the fair value of the identifiable net assets acquired, with a corresponding offset to goodwill, made during the measurement period related to the acquisitions of HireUp, Mint, and a local business. The Company may record additional adjustments related to these acquisitions during the remainder of the measurement period, which is not to exceed one year from the acquisition date. Upon conclusion of the measurement period, any subsequent adjustments will be recorded to earnings. See Note 4 - Acquisitions.

DEBT (Tables)

DEBT (Tables)	6 Months Ended
	Jun. 30, 2023
Debt Disclosure [Abstract]
Schedule of Long-term Debt	The Company's long-term debt consists of the following: June 30, 2023 December 31, 2022 Principal Debt Issuance Costs Principal Debt Issuance Costs (amounts in thousands) Term Loan, interest of 10.14% at December 31, 2022 $ — $ — $ 73,875 $ (1,940) Senior Secured Asset-Based Loan, interest of 6.66% and 5.90% at June 30, 2023 and December 31, 2022, respectively 31,000 (3,034) 76,800 (3,437) Long-term debt $ 31,000 $ (3,034) $ 150,675 $ (5,377)
Schedule of Aggregate Scheduled Maturities of Debt	As of June 30, 2023, the aggregate schedule for maturities of debt was as follows: Term Loan Senior Secured Asset-Based Loan (amounts in thousands) Through Years Ending December 31: 2023 $ — $ — 2024 — — 2025 — — 2026 — — 2027 — 31,000 Thereafter — — Total $ — $ 31,000

LEASES (Tables)

LEASES (Tables)	6 Months Ended
	Jun. 30, 2023
Leases [Abstract]
Schedule of Supplemental Balance Sheet Information	The table below presents the lease-related assets and liabilities included on the condensed consolidated balance sheets: Classification on Condensed Consolidated Balance Sheets: June 30, 2023 December 31, 2022 (amounts in thousands) Operating lease right-of-use assets $ 2,306 $ 3,254 Operating lease liabilities - current $ 3,292 $ 4,132 Operating lease liabilities - non-current $ 3,150 $ 4,880 June 30, 2023 December 31, 2022 Weighted average remaining lease term 2 years 2.3 years Weighted average discount rate 6.35 % 6.31 %
Schedule of Operating Lease Maturity	The table below reconciles the undiscounted cash flows for each of, and total of, the remaining years to the operating lease liabilities (which do not include short-term leases) recorded on the condensed consolidated balance sheets as of June 30, 2023: (amounts in thousands) Years Ending December 31: 2023 $ 1,989 2024 2,860 2025 1,913 2026 69 2027 47 Total minimum lease payments 6,878 Less: amount of lease payments representing interest (436) Present value of future minimum lease payments 6,442 Less: operating lease liabilities - current (3,292) Operating lease liabilities - non-current $ 3,150
Schedule of Lease Costs	The table below provides information regarding supplemental cash flows: Six Months Ended June 30, 2023 2022 (amounts in thousands) Supplemental Cash Flow Information: Cash paid for amounts included in the measurement of operating lease liabilities $ 2,434 $ 3,135 Right-of-use assets acquired under operating lease $ 88 $ 60 The components of lease expense are as follows: Three Months Ended June 30, 2023 2022 (amounts in thousands) Amounts Included in Condensed Consolidated Statements of Operations and Comprehensive Income: Operating lease expense $ 412 $ 645 Short-term lease expense $ 738 $ 1,241 Variable and other lease costs $ 275 $ (1,110) Six Months Ended June 30, 2023 2022 (amounts in thousands) Amounts Included in Condensed Consolidated Statements of Operations and Comprehensive Income: Operating lease expense $ 904 $ 1,447 Short-term lease expense $ 1,818 $ 2,385 Variable and other lease costs $ 273 $ (353)

FAIR VALUE MEASUREMENTS (Tables

FAIR VALUE MEASUREMENTS (Tables)	6 Months Ended
	Jun. 30, 2023
Fair Value Disclosures [Abstract]
Schedule of Estimated Fair Values of Financial Assets and Liabilities Measured on a Recurring Basis	The estimated fair value of the Company’s financial assets and liabilities measured on a recurring basis is as follows: Fair Value Measurements June 30, 2023 December 31, 2022 (amounts in thousands) Financial Assets: (Level 1) Deferred compensation asset $ 3,103 $ 2,477 Financial Liabilities: (Level 1) Deferred compensation liability $ 2,932 $ 2,507
Schedule of Carrying Amounts and Estimated Fair Values of Significant Financial Instrument that were not Measured at Fair Value	The carrying amounts and estimated fair value of the Company’s significant financial instruments that were not measured at fair value are as follows: June 30, 2023 December 31, 2022 Carrying Fair Carrying Fair (amounts in thousands) Financial Liabilities: (Level 2) Senior Secured Asset-Based Loan $ 31,000 $ 31,000 $ 76,800 $ 76,800 Term Loan, net $ — $ — $ 73,875 $ 71,221 Earnout Liability (WSG) $ 7,500 $ 7,500 $ 7,500 $ 7,500 Earnout Liability (Mint) $ 10,000 $ 10,000 $ 10,000 $ 10,000 Earnout Liability (HireUp) $ 3,500 $ 3,500 $ 8,000 $ 8,000

STOCKHOLDERS' EQUITY (Tables)

STOCKHOLDERS' EQUITY (Tables)	6 Months Ended
	Jun. 30, 2023
Equity [Abstract]
Schedule of Restricted Stock Activity	The following table summarizes restricted stock awards and performance stock awards activity issued under the 2017 Plan and the 2020 Plan (Plans) for the six months ended June 30, 2023: Restricted Stock Awards Performance Stock Awards Number of Weighted Number of Target Weighted Unvested restricted stock awards, January 1, 2023 674,508 $ 14.53 476,086 $ 12.56 Granted 314,503 $ 22.80 200,487 $ 19.23 Vested (402,419) $ 12.40 (238,253) $ 6.74 Forfeited (21,405) $ 20.93 (4,785) $ 16.83 Unvested restricted stock awards, June 30, 2023 565,187 $ 20.40 433,535 $ 18.80

SEGMENT DATA (Tables)

SEGMENT DATA (Tables)	6 Months Ended
	Jun. 30, 2023
Segment Reporting [Abstract]
Schedule of Information on Operating Segments and Reconciliation to Income from Operations	Information on operating segments and a reconciliation to income from operations for the periods indicated are as follows: Three Months Ended Six Months Ended June 30, June 30, 2023 2022 2023 2022 (amounts in thousands) Revenue from services: Nurse and Allied Staffing $ 495,376 $ 731,443 $ 1,077,678 $ 1,497,023 Physician Staffing 45,319 22,118 85,724 45,270 $ 540,695 $ 753,561 $ 1,163,402 $ 1,542,293 Contribution income: Nurse and Allied Staffing $ 56,481 $ 97,567 $ 123,650 $ 207,668 Physician Staffing 3,541 1,220 5,265 2,985 60,022 98,787 128,915 210,653 Corporate overhead (a) 18,891 17,583 37,547 33,837 Depreciation and amortization 4,432 3,481 9,336 6,200 Restructuring costs (benefits) 913 (1,114) 1,342 (634) Legal settlement charges — — 1,125 — Impairment charges 533 — 533 1,741 Other costs (b) 64 — 46 40 Income from operations $ 35,189 $ 78,837 $ 78,986 $ 169,469 _______________ (a) Corporate overhead includes unallocated executive leadership and other centralized corporate functional support costs such as finance, IT, legal, human resources, and marketing, as well as public company expenses and corporate-wide projects (initiatives). (b) Other costs include acquisition and integration-related (benefits) costs.

SUMMARY OF SIGNIFICANT ACCOUN_4

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Details) - USD ($) $ in Millions	6 Months Ended
	Jun. 30, 2023	Dec. 31, 2022
Accounts, Notes, Loans and Financing Receivable [Line Items]
Unbilled contracts receivable	$ 116.9	$ 152.4
Sales allowance, billing-related adjustments	$ 1.9	$ 1.6
Minimum
Accounts, Notes, Loans and Financing Receivable [Line Items]
Threshold period, past due for payment of services provided	30 days
Maximum
Accounts, Notes, Loans and Financing Receivable [Line Items]
Threshold period, past due for payment of services provided	60 days

SUMMARY OF SIGNIFICANT ACCOUN_5

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Allowance for Doubtful Accounts (Details) - USD ($) $ in Thousands	3 Months Ended				6 Months Ended
	Jun. 30, 2023	Mar. 31, 2023	Jun. 30, 2022	Mar. 31, 2022	Jun. 30, 2023	Jun. 30, 2022
Accounts Receivable, Allowance for Credit Loss [Roll Forward]
Beginning balance	$ 18,020	$ 13,058	$ 8,091	$ 6,087	$ 13,058	$ 6,087
Bad Debt Expense	3,134	4,908	3,192	2,369	8,042	5,561
Write-Offs, net of Recoveries	(4,240)	54	(426)	(365)
Ending balance	$ 16,914	$ 18,020	$ 10,857	$ 8,091	$ 16,914	$ 10,857

SUMMARY OF SIGNIFICANT ACCOUN_6

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Restructuring (Benefits) Costs (Details) - USD ($) $ in Thousands	3 Months Ended			6 Months Ended
	Jun. 30, 2023	Mar. 31, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Restructuring Reserve [Roll Forward]
Charged (credited) to restructuring	$ 913		$ (1,114)	$ 1,342	$ (634)
Employee Termination Costs
Restructuring Reserve [Roll Forward]
Balance at beginning of period	787	$ 799		799
Charged (credited) to restructuring	913	527
Payments and adjustments	(608)	(539)
Balance at end of period	1,092	787		1,092
Lease-Related Exit Costs
Restructuring Reserve [Roll Forward]
Balance at beginning of period	1,800	2,196		2,196
Charged (credited) to restructuring	0	(98)
Payments and adjustments	(288)	(298)
Balance at end of period	$ 1,512	$ 1,800		$ 1,512

REVENUE RECOGNITION (Details)

REVENUE RECOGNITION (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Disaggregation of Revenue [Line Items]
Revenue from services	$ 540,695	$ 753,561	$ 1,163,402	$ 1,542,293
Temporary Staffing Services
Disaggregation of Revenue [Line Items]
Revenue from services	526,675	733,297	1,132,522	1,504,848
Other Services
Disaggregation of Revenue [Line Items]
Revenue from services	14,020	20,264	30,880	37,445
Nurse And Allied Staffing
Disaggregation of Revenue [Line Items]
Revenue from services	495,376	731,443	1,077,678	1,497,023
Nurse And Allied Staffing | Temporary Staffing Services
Disaggregation of Revenue [Line Items]
Revenue from services	483,560	712,090	1,051,210	1,461,537
Nurse And Allied Staffing | Other Services
Disaggregation of Revenue [Line Items]
Revenue from services	11,816	19,353	26,468	35,486
Physician Staffing
Disaggregation of Revenue [Line Items]
Revenue from services	45,319	22,118	85,724	45,270
Physician Staffing | Temporary Staffing Services
Disaggregation of Revenue [Line Items]
Revenue from services	43,115	21,207	81,312	43,311
Physician Staffing | Other Services
Disaggregation of Revenue [Line Items]
Revenue from services	$ 2,204	$ 911	$ 4,412	$ 1,959

ACQUISITIONS (Details)

ACQUISITIONS (Details) - USD ($) $ in Thousands

3 Months Ended

Dec. 15, 2022

Dec. 13, 2022

Oct. 03, 2022

Dec. 16, 2021

Jun. 08, 2021

Mar. 31, 2023

Sep. 30, 2022

Jun. 30, 2022

Dec. 31, 2021

Sep. 30, 2021

Jun. 30, 2023

Dec. 31, 2022

Business Acquisition [Line Items]

Current portion of earnout liability

$ 15,800

$ 7,500

Non-current portion of earnout liability

5,200

18,000

Goodwill

137,020

$ 163,268

HireUp

Business Acquisition [Line Items]

Cash consideration, gross

$ 6,000

Equity consideration for acquisition, value

$ 800

Equity consideration for acquisition (shares)

29,811

Earnout liabilities

$ 8,000

Current portion of earnout liability

3,300

Non-current portion of earnout liability

200

Other intangible assets

$ 6,900

Weighted average useful life

7 years

Goodwill

$ 3,100

HireUp | Trade names

Business Acquisition [Line Items]

Other intangible assets

$ 900

Weighted average useful life

2 years

HireUp | Customer Lists

Business Acquisition [Line Items]

Other intangible assets

$ 2,500

Weighted average useful life

10 years

HireUp | Databases

Business Acquisition [Line Items]

Other intangible assets

$ 3,500

Weighted average useful life

7 years

Mint

Business Acquisition [Line Items]

Cash consideration, gross

$ 27,000

Equity consideration for acquisition, value

$ 3,600

Equity consideration for acquisition (shares)

114,278

Earnout liabilities

$ 10,000

Current portion of earnout liability

5,000

Non-current portion of earnout liability

5,000

Other intangible assets

$ 15,100

Weighted average useful life

7 years

Goodwill

$ 20,100

Mint | Trade names

Business Acquisition [Line Items]

Other intangible assets

$ 400

Weighted average useful life

1 year

Mint | Customer Lists

Business Acquisition [Line Items]

Other intangible assets

$ 2,300

Weighted average useful life

11 years

Mint | Databases

Business Acquisition [Line Items]

Other intangible assets

$ 12,400

Weighted average useful life

7 years

Local Business

Business Acquisition [Line Items]

Cash consideration, gross

$ 2,000

Goodwill

$ 0

Selected, Inc

Business Acquisition [Line Items]

Cash consideration, gross

$ 3,500

Equity consideration for acquisition, value

$ 1,500

Equity consideration for acquisition (shares)

59,429

Earnout liabilities

$ 1,500

Other intangible assets

$ 4,600

Weighted average useful life

5 years

Goodwill

$ 400

Selected, Inc | Trade names

Business Acquisition [Line Items]

Other intangible assets

$ 0

Weighted average useful life

2 years

Selected, Inc | Databases

Business Acquisition [Line Items]

Other intangible assets

$ 2,900

Weighted average useful life

5 years

Selected, Inc | Software

Business Acquisition [Line Items]

Other intangible assets

$ 1,700

Weighted average useful life

5 years

Workforce Solutions Group, Inc.

Business Acquisition [Line Items]

Cash consideration, gross

$ 25,000

Equity consideration for acquisition, value

$ 5,000

Equity consideration for acquisition (shares)

307,730

Earnout liabilities

$ 15,000

Current portion of earnout liability

$ 7,500

Goodwill

22,100

Net working capital adjustment

$ 1,100

Escrow account

$ 2,000

Contingent consideration liability, term

3 years

Payment of contingent consideration

$ 7,500

Workforce Solutions Group, Inc. | Customer relationships

Business Acquisition [Line Items]

Other intangible assets

$ 14,200

Weighted average useful life

11 years 6 months

COMPREHENSIVE INCOME (Details)

COMPREHENSIVE INCOME (Details) - USD ($) $ in Millions	Jun. 30, 2023	Dec. 31, 2022
Equity [Abstract]
Loss on currency fluctuations	$ 1.4	$ 1.5

EARNINGS PER SHARE - Components

EARNINGS PER SHARE - Components of Numerator and Denominator for Computation of Basic and Diluted Earnings per Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Numerator:
Net income attributable to common stockholders - Basic	$ 21,345	$ 52,894	$ 50,781	$ 114,877
Net income attributable to common stockholders - Diluted	$ 21,345	$ 52,894	$ 50,781	$ 114,877
Denominator:
Weighted average common shares - Basic (shares)	35,351	37,471	35,606	37,251
Effect of diluted shares:
Share-based awards (shares)	173	286	435	615
Weighted average common shares - Diluted (shares)	35,524	37,757	36,041	37,866
Net income per share attributable to common stockholders - Basic (in dollars per share)	$ 0.60	$ 1.41	$ 1.43	$ 3.08
Net income per share attributable to common stockholders - Diluted (in dollars per share)	$ 0.60	$ 1.40	$ 1.41	$ 3.03

EARNINGS PER SHARE - Anti-dilut

EARNINGS PER SHARE - Anti-dilutive Securities (Details) - shares shares in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Share-Based Payment Arrangement
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Share-based awards (shares)	0	220	0	110

GOODWILL, TRADE NAMES, AND OT_3

GOODWILL, TRADE NAMES, AND OTHER INTANGIBLE ASSETS - Acquired Intangible Assets (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Intangible assets subject to amortization:
Gross Carrying Amount	$ 104,902	$ 82,902
Accumulated Amortization	50,631	44,079
Net Carrying Amount	54,271	38,823
Intangible assets not subject to amortization:
Trade names, indefinite-lived	5,900	5,900
Databases
Intangible assets subject to amortization:
Gross Carrying Amount	49,330	33,430
Accumulated Amortization	25,447	22,033
Net Carrying Amount	23,883	11,397
Customer relationships
Intangible assets subject to amortization:
Gross Carrying Amount	52,538	47,738
Accumulated Amortization	24,011	21,672
Net Carrying Amount	28,527	26,066
Non-compete agreements
Intangible assets subject to amortization:
Gross Carrying Amount	4	4
Accumulated Amortization	4	3
Net Carrying Amount	0	1
Trade names
Intangible assets subject to amortization:
Gross Carrying Amount	1,330	30
Accumulated Amortization	644	16
Net Carrying Amount	686	14
Software
Intangible assets subject to amortization:
Gross Carrying Amount	1,700	1,700
Accumulated Amortization	525	355
Net Carrying Amount	$ 1,175	$ 1,345

GOODWILL, TRADE NAMES, AND OT_4

GOODWILL, TRADE NAMES, AND OTHER INTANGIBLE ASSETS - Estimated Annual Amortization Expense (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
2023	$ 5,702
2024	10,481
2025	9,571
2026	8,362
2027	6,191
Thereafter	13,964
Net Carrying Amount	$ 54,271	$ 38,823

GOODWILL, TRADE NAMES, AND OT_5

GOODWILL, TRADE NAMES, AND OTHER INTANGIBLE ASSETS - Goodwill Rollforward (Details) $ in Thousands	6 Months Ended
	Jun. 30, 2023 USD ($)
Goodwill [Roll Forward]
Aggregate goodwill acquired, beginning balance	$ 473,740
Accumulated impairment loss, beginning balance	(310,472)
Goodwill, net of impairment loss, beginning balance	163,268
Goodwill acquisition adjustments	(26,248)
Aggregate goodwill acquired, ending balance	447,492
Accumulated impairment loss, ending balance	(310,472)
Goodwill, net of impairment loss, ending balance	137,020
Nurse And Allied Staffing
Goodwill [Roll Forward]
Aggregate goodwill acquired, beginning balance	395,119
Accumulated impairment loss, beginning balance	(269,874)
Goodwill, net of impairment loss, beginning balance	125,245
Goodwill acquisition adjustments	(11,148)
Aggregate goodwill acquired, ending balance	383,971
Accumulated impairment loss, ending balance	(269,874)
Goodwill, net of impairment loss, ending balance	114,097
Physician Staffing
Goodwill [Roll Forward]
Aggregate goodwill acquired, beginning balance	78,621
Accumulated impairment loss, beginning balance	(40,598)
Goodwill, net of impairment loss, beginning balance	38,023
Goodwill acquisition adjustments	(15,100)
Aggregate goodwill acquired, ending balance	63,521
Accumulated impairment loss, ending balance	(40,598)
Goodwill, net of impairment loss, ending balance	$ 22,923

GOODWILL, TRADE NAMES, AND OT_6

GOODWILL, TRADE NAMES, AND OTHER INTANGIBLE ASSETS - Additional Information (Details) $ in Millions	3 Months Ended
	Jun. 30, 2023 USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
Impairment charge	$ 0.5

DEBT - Long-term Debt (Details)

DEBT - Long-term Debt (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Debt Instrument [Line Items]
Long-term debt	$ 31,000	$ 150,675
Debt Issuance Costs	(3,034)	$ (5,377)
Term Loan | 2021 Term Loan Credit Agreement
Debt Instrument [Line Items]
Effective interest rate percentage		10.14%
Long-term debt	0	$ 73,875
Debt Issuance Costs	$ 0	$ (1,940)
Senior Secured Asset-Based Loan | Senior Secured Asset-Based Loan
Debt Instrument [Line Items]
Effective interest rate percentage	6.66%	5.90%
Long-term debt	$ 31,000	$ 76,800
Debt Issuance Costs	$ (3,034)	$ (3,437)

DEBT - 2021 Term Loan Credit Ag

DEBT - 2021 Term Loan Credit Agreement Narrative (Details) - USD ($)

3 Months Ended

4 Months Ended

6 Months Ended

9 Months Ended

Jun. 30, 2023

Apr. 14, 2023

Oct. 26, 2022

Jun. 23, 2022

Jun. 08, 2021

Jun. 30, 2023

Dec. 31, 2022

Jun. 30, 2022

Oct. 26, 2022

Jun. 30, 2023

Jun. 30, 2022

Dec. 31, 2022

Nov. 18, 2021

Debt Instrument [Line Items]

Repayment of outstanding obligations

$ 73,875,000

$ 50,438,000

Term Loan | 2021 Term Loan Credit Agreement

Debt Instrument [Line Items]

Payment for debt prepayment

$ 50,000,000

$ 50,000,000

$ 100,000,000

$ 100,000,000

Debt term

6 years

Face amount

$ 100,000,000

Prepayment premium paid

$ 0

$ 1,000,000

Write off of debt issuance costs

$ 1,700,000

$ 1,300,000

$ 1,400,000

Repayment of outstanding obligations

$ 73,900,000

Term Loan | 2021 Term Loan Credit Agreement | LIBOR

Debt Instrument [Line Items]

Interest margin percentage

5.75%

Interest margin floor percentage

0.75%

Term Loan | 2021 Term Loan Credit Agreement | SOFR

Debt Instrument [Line Items]

Basis spread on variable rate, additional credit spread associated with SOFR

0.10%

Term Loan | 2021 Term Loan Credit Agreement, Incremental Term Loan

Debt Instrument [Line Items]

Face amount

$ 75,000,000

Term Loan | 2021 Term Loan Credit Agreement, Aggregate Amount of All Possible Increases

Debt Instrument [Line Items]

Face amount

$ 115,000,000

DEBT - Maturities of Debt (Deta

DEBT - Maturities of Debt (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Long-term Debt, Fiscal Year Maturity [Abstract]
Total debt	$ 31,000	$ 150,675
Term Loan | 2021 Term Loan Credit Agreement
Long-term Debt, Fiscal Year Maturity [Abstract]
2023	0
2024	0
2025	0
2026	0
2027	0
Thereafter	0
Total debt	0	73,875
Senior Secured Asset-Based Loan | Senior Secured Asset-Based Loan
Long-term Debt, Fiscal Year Maturity [Abstract]
2023	0
2024	0
2025	0
2026	0
2027	31,000
Thereafter	0
Total debt	$ 31,000	$ 76,800

DEBT - 2019 Asset-Based Loan Ag

DEBT - 2019 Asset-Based Loan Agreement (Details) - USD ($)			6 Months Ended
	Mar. 21, 2022	Oct. 25, 2019	Jun. 30, 2023	Nov. 18, 2021	Mar. 08, 2021	Jun. 30, 2020
Line of Credit Facility [Line Items]
Amount of indebtedness permitted from other sources				$ 175,000,000
Senior Secured Asset-Based Loan
Line of Credit Facility [Line Items]
Line of credit term	5 years	5 years
Maximum borrowing capacity	$ 300,000,000	$ 120,000,000			$ 150,000,000	$ 130,000,000
Borrowing base, percentage of assets		85%
Borrowing base availability			$ 289,200,000
Line of credit, carrying amount			31,000,000
Letters of credit outstanding			18,200,000
Borrowing availability			$ 240,000,000
Quarterly commitment fee on the average daily unused portion percentage			0.375%
Senior Secured Asset-Based Loan | SOFR
Line of Credit Facility [Line Items]
Basis spread on variable rate, additional credit spread associated with SOFR	0.10%
Interest margin percentage			1.60%
Senior Secured Asset-Based Loan | Base Rate
Line of Credit Facility [Line Items]
Interest margin percentage			0.50%
Senior Secured Asset-Based Loan | Swingline Sublimit
Line of Credit Facility [Line Items]
Maximum borrowing capacity		$ 15,000,000
Senior Secured Asset-Based Loan | Standby Letters Of Credit Sublimit
Line of Credit Facility [Line Items]
Maximum borrowing capacity		$ 35,000,000

LEASES - Additional Information

LEASES - Additional Information (Details) - USD ($)	3 Months Ended			6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Mar. 31, 2022	Jun. 30, 2023
Leases [Abstract]
Operating lease, impairment loss	$ 0	$ 0	$ 1,500,000	$ 0
Impairment of long-lived assets held-for-use	$ 0	$ 0	$ 0	$ 0

LEASES - Supplemental Balance S

LEASES - Supplemental Balance Sheet Information (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Leases [Abstract]
Operating lease right-of-use assets	$ 2,306	$ 3,254
Operating lease liabilities - current	3,292	4,132
Operating lease liabilities - non-current	$ 3,150	$ 4,880
Weighted average remaining lease term	2 years	2 years 3 months 18 days
Weighted average discount rate	6.35%	6.31%

LEASES - Operating Lease Maturi

LEASES - Operating Lease Maturity (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Leases [Abstract]
2023	$ 1,989
2024	2,860
2025	1,913
2026	69
2027	47
Total minimum lease payments	6,878
Less: amount of lease payments representing interest	(436)
Present value of future minimum lease payments	6,442
Less: operating lease liabilities - current	(3,292)	$ (4,132)
Operating lease liabilities - non-current	$ 3,150	$ 4,880

LEASES - Lease Costs (Details)

LEASES - Lease Costs (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Leases [Abstract]
Cash paid for amounts included in the measurement of operating lease liabilities			$ 2,434	$ 3,135
Right-of-use assets acquired under operating lease			88	60
Operating lease expense	$ 412	$ 645	904	1,447
Short-term lease expense	738	1,241	1,818	2,385
Variable and other lease costs	$ 275	$ (1,110)	$ 273	$ (353)

FAIR VALUE MEASUREMENTS - Estim

FAIR VALUE MEASUREMENTS - Estimated Fair Values of Financial Assets and Liabilities Measured on a Recurring Basis (Details) - Level 1 - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Deferred Compensation
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Deferred compensation liability	$ 2,932	$ 2,507
Deferred Compensation
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Deferred compensation asset	$ 3,103	$ 2,477

FAIR VALUE MEASUREMENTS - Narra

FAIR VALUE MEASUREMENTS - Narrative (Details) - USD ($) $ in Thousands		3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2023	Sep. 30, 2022	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2022
Fair Value Measurement [Line Items]
Impairment charge		$ 500
Repayment of outstanding obligations				$ 73,875	$ 50,438
Current portion of earnout liability	$ 15,800	15,800		15,800		$ 7,500
Non-current earnout liability	5,200	5,200		5,200		$ 18,000
Workforce Solutions Group, Inc.
Fair Value Measurement [Line Items]
Payment of contingent consideration			$ 7,500
Current portion of earnout liability	7,500	7,500		7,500
Mint
Fair Value Measurement [Line Items]
Current portion of earnout liability	5,000	5,000		5,000
Non-current earnout liability	5,000	5,000		5,000
HireUp
Fair Value Measurement [Line Items]
Current portion of earnout liability	3,300	3,300		3,300
Non-current earnout liability	200	$ 200		$ 200
2021 Term Loan Credit Agreement | Term Loan
Fair Value Measurement [Line Items]
Repayment of outstanding obligations	$ 73,900

FAIR VALUE MEASUREMENTS - Carry

FAIR VALUE MEASUREMENTS - Carrying Amounts and Estimated Fair Values of Significant Financial Instrument that were not Measured at Fair Value (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022	Dec. 13, 2022	Oct. 03, 2022	Jun. 08, 2021
Workforce Solutions Group, Inc.
Fair Value, Option, Quantitative Disclosures [Line Items]
Earnout liability					$ 15,000
Mint
Fair Value, Option, Quantitative Disclosures [Line Items]
Earnout liability				$ 10,000
HireUp
Fair Value, Option, Quantitative Disclosures [Line Items]
Earnout liability			$ 8,000
Level 2 | Carrying Amount | Workforce Solutions Group, Inc.
Fair Value, Option, Quantitative Disclosures [Line Items]
Earnout liability	$ 7,500	$ 7,500
Level 2 | Carrying Amount | Mint
Fair Value, Option, Quantitative Disclosures [Line Items]
Earnout liability	10,000	10,000
Level 2 | Carrying Amount | HireUp
Fair Value, Option, Quantitative Disclosures [Line Items]
Earnout liability	3,500	8,000
Level 2 | Fair Value | Workforce Solutions Group, Inc.
Fair Value, Option, Quantitative Disclosures [Line Items]
Earnout liability	7,500	7,500
Level 2 | Fair Value | Mint
Fair Value, Option, Quantitative Disclosures [Line Items]
Earnout liability	10,000	10,000
Level 2 | Fair Value | HireUp
Fair Value, Option, Quantitative Disclosures [Line Items]
Earnout liability	3,500	8,000
Level 2 | Senior Secured Asset-Based Loan | Carrying Amount
Fair Value, Option, Quantitative Disclosures [Line Items]
Senior Secured Asset-Based Loan	31,000	76,800
Level 2 | Senior Secured Asset-Based Loan | Fair Value
Fair Value, Option, Quantitative Disclosures [Line Items]
Senior Secured Asset-Based Loan	31,000	76,800
Level 2 | Term Loan | Carrying Amount
Fair Value, Option, Quantitative Disclosures [Line Items]
Term Loan, net	0	73,875
Level 2 | Term Loan | Fair Value
Fair Value, Option, Quantitative Disclosures [Line Items]
Term Loan, net	$ 0	$ 71,221

STOCKHOLDERS' EQUITY - Addition

STOCKHOLDERS' EQUITY - Additional Information (Details) - USD ($) $ / shares in Units, $ in Thousands		3 Months Ended			6 Months Ended
	May 19, 2020	Jun. 30, 2023	Mar. 31, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022	May 01, 2023	Aug. 16, 2022
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock repurchase and retirement		$ 4,723			$ 36,483
Unrestricted shares of common stock outstanding (shares)		35,305,025			35,305,025
Performance attainment percentage			120%
Restricted Stock And Performance Shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vested in period, net (shares)		49,582		80,200	424,274	499,700
Performance Stock Awards
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vested (shares)			238,253		238,253
Selling, General and Administrative Expenses
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation		$ 2,200		$ 2,100	$ 4,000	$ 3,700
Omnibus Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares reserved for share-based payments (shares)	3,000,000
Omnibus Plan | Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	1 year
New Repurchase Program
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock repurchase program, authorized amount								$ 100,000
Additional authorized amount							$ 59,000
Common shares amount left remaining to repurchase under the plan (up to)		$ 98,400			$ 98,400		$ 100,000
Shares repurchased and retired (shares)		198,463			1,421,867
Stock repurchase and retirement		$ 4,700			$ 36,500
Average market price (in dollars per share)		$ 23.78			$ 25.64
Prior Repurchase Program
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares repurchased and retired (shares)				0		0

STOCKHOLDERS' EQUITY - Restrict

STOCKHOLDERS' EQUITY - Restricted Stock Activity (Details) - $ / shares	3 Months Ended	6 Months Ended
	Mar. 31, 2023	Jun. 30, 2023
Restricted Stock Awards
Number of Shares
Unvested restricted stock awards, beginning balance (shares)	674,508	674,508
Granted (shares)		314,503
Vested (shares)		(402,419)
Forfeited (shares)		(21,405)
Unvested restricted stock awards, ending balance (shares)		565,187
Weighted Average Grant Date Fair Value
Unvested restricted stock awards, beginning balance (in dollars per share)	$ 14.53	$ 14.53
Granted (in dollars per share)		22.80
Vested (in dollars per share)		12.40
Forfeited (in dollars per share)		20.93
Unvested restricted stock awards, ending balance (in dollars per share)		$ 20.40
Performance Stock Awards
Number of Shares
Unvested restricted stock awards, beginning balance (shares)	476,086	476,086
Granted (shares)		200,487
Vested (shares)	(238,253)	(238,253)
Forfeited (shares)		(4,785)
Unvested restricted stock awards, ending balance (shares)		433,535
Weighted Average Grant Date Fair Value
Unvested restricted stock awards, beginning balance (in dollars per share)	$ 12.56	$ 12.56
Granted (in dollars per share)		19.23
Vested (in dollars per share)		6.74
Forfeited (in dollars per share)		16.83
Unvested restricted stock awards, ending balance (in dollars per share)		$ 18.80

SEGMENT DATA (Details)

SEGMENT DATA (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Revenue from services	$ 540,695	$ 753,561	$ 1,163,402	$ 1,542,293
Contribution income:	60,022	98,787	128,915	210,653
Corporate overhead	18,891	17,583	37,547	33,837
Depreciation and amortization	4,432	3,481	9,336	6,200
Restructuring costs (benefits)	913	(1,114)	1,342	(634)
Legal settlement charges	0	0	1,125	0
Impairment charges	533	0	533	1,741
Other costs	64	0	46	40
Income from operations	35,189	78,837	78,986	169,469
Nurse and Allied Staffing
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Revenue from services	495,376	731,443	1,077,678	1,497,023
Contribution income:	56,481	97,567	123,650	207,668
Physician Staffing
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Revenue from services	45,319	22,118	85,724	45,270
Contribution income:	$ 3,541	$ 1,220	$ 5,265	$ 2,985

INCOME TAXES (Details)

INCOME TAXES (Details)	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Income Tax Disclosure [Abstract]
Effective tax rate	29.60%	28.70%	27.90%	28.80%
Effective tax rate, excluding discrete items	30%	28.90%	30%	29.50%

RELATED PARTY TRANSACTIONS (Det

RELATED PARTY TRANSACTIONS (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2022
Related Party Transaction [Line Items]
Revenue	$ 540,695,000	$ 753,561,000	$ 1,163,402,000	$ 1,542,293,000
Accounts payable and accrued expenses	139,555,000		139,555,000		$ 185,507,000
Affiliated Entity | Services Provided Entities Affiliated with Board Members
Related Party Transaction [Line Items]
Revenue	400,000	$ 500,000	600,000	$ 900,000
Related Party | Rental of WSG's Headquarters
Related Party Transaction [Line Items]
Rent expense	0
Accounts payable and accrued expenses	$ 0		$ 0